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PREFACE
I am a Fulbright scholar and registered pharmacist from Malaysia who came
to the United States to study healthcare management and health policy. I work at the
Ministry of Health Malaysia where I was involved with the national medicines policy
and healthcare reform initiative prior to starting my PhD program. I am interested in
cancer health disparities, which is a global public health problem. This is in part due
to more people surviving cancer as a result of advancement in treatment technology
and pharmaceutical discoveries that comes with increasing financial burden. I am
particularly interested in further understanding current disparities in access to and
quality of cancer care, and learning about the medical financial hardship among
cancer survivors. My future aim is to effectively engage with pharmaceutical
stakeholders in the public and private sectors to establish an affordable and
sustainable financing mechanism to achieve universal access to medicines.
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Untreated chronic phase chronic myeloid leukemia (CML) will eventually
progress to advanced phase in 3 to 5 years. Treating CML with tyrosine kinase
inhibitors (TKIs) has turned it into a chronic, manageable disease where most
patients experience near normal life expectancy, particularly those diagnosed before
age 65 years. Patients are required to continuously take their oral TKIs daily to
produce the anticipated benefit of long-term survival. High out-of-pocket costs may
lead to disparities in the initiation of and subsequent adherence to these expensive
TKIs. Therefore, the goal of this dissertation is to assess the relationship between
patient prescription cost sharing, TKIs initiation and adherence, and healthcare
utilization and costs in a large group of commercially insured patients with newly
diagnosed CML. The objective is twofold: 1) determine how patient cost sharing of
TKI affects initiation, and healthcare utilization and costs, and 2) examine the
association between TKI out-of-pocket costs, adherence, and healthcare utilization

and costs. For these two objectives, we conducted a retrospective cohort study
using longitudinal medical and pharmacy claims data from IBM® MarketScan®
Commercial Database from 2011 to 2015. We included patients who were recently
diagnosed with CML and filled at least one prescription for TKI. We found that high
out-of-pocket costs for TKI medications put patients at increased risk of nonadherence. Patients with early initiation of TKI and better adherence had higher TKI
medication costs, but experienced fewer hospitalizations, resulting in lower medical
and total annual healthcare costs. In summary, our findings suggest that high drug
out-of-pocket costs may limit access to life-saving oral anticancer medications,
causing disparities in TKI initiation and adherence for CML treatment. Oral
anticancer medications are typically covered under a pharmacy benefit with
substantial out-of-pocket costs due at the time the medication is obtained at the
pharmacy. Efforts to lower drug prices and subsequently, the out-of-pocket costs for
TKI medications could significantly improve adherence, and overall health and
economic outcomes among CML patients.
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BACKGROUND
Literature Review
Cancer and Targeted Therapies
In the United States, cancer comes in second among all causes of death after
heart disease. 1 However, the 5-year relative survival rate for all cancers diagnosed
between 2004 and 2010 was 68%, an improvement from 49% three decades before,
which reflects earlier diagnosis of certain cancers and advancement in treatment
technology. 2 There are more Americans surviving cancer over a 10-year period with
current statistics showing approximately 15.5 million cancer survivors in January
2016 3 in comparison to 11.4 million in January 2006 4. The Agency for Healthcare
Research and Quality (AHRQ) estimated that the direct medical costs for cancer in
the United States were $88.7 billion in 2011 with 11% being spent on prescription
drugs. 2 Between 2010 and 2020, national costs of cancer care were projected to
increase 27% from $125 billion to $158 billion with only growth and aging in
population accounting for this increase in costs, but if incidence, survival, and cost
trends were also taken into account, the projected 2020 costs could go as high as
$173 billion, showing a 39% increase instead. 5
Much anticancer drug development has focused on targeted therapies. 6 The
use of targeted therapies in cancer grew from 11% in 2003 to 46% in 2013 7
because additional indications for such drugs approved in the early 2000’s led to
their increased uptake, affecting the use of traditional cytotoxic and hormonal
1

therapies 8. Targeted cancer therapies inhibit molecular targets involved in the
growth, progression, and spread of cancer 6. Chronic myeloid leukemia (CML) cells
contain a BCR-ABL oncogene not found in normal cells, which makes a BCR-ABL
protein that causes CML cells to grow and reproduce unchecked. 9 This type of
protein is known as a tyrosine kinase, and the standard treatment for CML is
tyrosine kinase inhibitors (TKIs), drugs that target BCR-ABL. 9
Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
CML accounts for 15% of adult leukemias. 10 The median age at diagnosis is
65 years; however, CML occurs in all age groups with 47.7% of new cases
diagnosed among people aged 20-64. 11 In 2018, an estimated 8,430 people are
expected to be diagnosed with CML in the United States, and 1,090 people are
expected to die from the disease. 11
CML occurs in three different phases (chronic, accelerated, and blast phase),
and is usually diagnosed in the chronic phase. 10 Untreated chronic phase CML will
eventually progress to advanced phase in 3 to 5 years. 12 Imatinib, dasatinib, and
nilotinib are recommended as first-line TKI therapy for newly diagnosed patients with
chronic phase CML, followed by bosutinib and ponatinib as second line options.
10,13,14

Imatinib [Gleevec, Novartis], was the first TKI approved by the US Food and

Drug Administration (FDA) for CML treatment in 2001, followed by dasatinib
[Sprycel, Bristol-Myers Squibb] in 2006, nilotinib [Tasigna, Novartis] in 2007, and
bosutinib [Bosulif, Pfizer] and ponatinib [Iclusig, Ariad Pharmaceuticals] in 2012. 15
2

TKIs are considered to be the most successful class of targeted cancer
therapies, exceeding all survival expectations. 16 Before TKIs, a stem cell transplant
was considered the treatment of choice for CML, but this complicated treatment can
cause serious side effects 17, and is no longer recommended as the first-line option
for patients with chronic phase CML 10. TKIs play a large part in more than doubling
the 5-year survival rate for CML over the past two decades, from 31% for patients
diagnosed in the early 1990’s to 66% for those diagnosed from 2006 to 2012 3. The
median survival used to be 4 to 6 years, but today most CML patients treated with
TKIs experience near normal life expectancy, particularly those diagnosed before
age 65 years. 18,19
Treating CML with TKIs has differentiated the condition from solid cancers,
such as sarcomas, carcinomas, or lymphomas, turning it into a chronic, manageable
disease similar to diabetes, hypertension, and cardiovascular disorders. 13,16 Patients
are required to continuously take their oral TKIs daily to produce the anticipated
benefit of long-term survival. Despite significant clinical benefits, several studies
employing a variety of methods for measuring patient adherence have demonstrated
10-98% adherence to approved TKIs. 20-27 Non-adherent patients not only get fewer
therapy benefits, but they also face risk of treatment failure due to resistant CML.
21,23

Economic Burden of Chronic Myeloid Leukemia
Much attention has been focused on the high cost of TKIs and whether these
3

costs inhibit patient use. 16 Anticancer drug prices have more than doubled from an
average of $5,000 per month a decade ago to more than $10,000 per month. 16
Imatinib was initially priced at nearly $30,000 per year when it was released in 2001,
and its price tripled to $92,000 per year in 2012. 16 Imatinib, as one of the most
successful targeted cancer therapies, may have paved the way for the rising cost of
anticancer drugs. 16 Bosutinib and ponatinib, both introduced in 2012, were priced at
$118,000 and $138,000 per year respectively. 16 These estimates are based on
average wholesale prices, however, and would not be actual prices paid by patients
with health insurance coverage. 28
People with health insurance have a better chance of surviving cancer than
people who are uninsured. Newly diagnosed CML patients in the United States who
were uninsured or had Medicaid were associated with worse 5-year overall survival
in comparison with being insured. 29 Having prescription drug coverage is an
important determinant for cost-related medication non-adherence. 30 Prescription
drug coverage protects the patients from having to pay the full price of a drug out-ofpocket. Even so, the financial protection by prescription drug coverage differed
considerably by source of coverage with rates of out-of-pocket cost-related
medication non-adherence ranging from 9% if patients had the Veterans Affairs drug
coverage to 18% with private insurance, 25% with Medicare, and 31% with
Medicaid. 31
In order to control costs, prescription drug plans in the United States tend to
4

have cost-sharing mechanisms that can result in patients initiating anticancer drugs
facing high out-of-pocket costs. 32 Cost-sharing mechanisms such as higher
copayment amounts, co-insurance, or annual deductibles 33-35 shift the financial risks
of the high-cost drugs from the plan to the patients, which then can cause them to
become non-adherent to their cancer treatment 36. Cost sharing has reduced
outpatient prescription drug spending growth from 16% in 2000 to 8% in 2004. 37
Increased cost sharing reduces prescription medication use. 30,38 To reduce
out-of-pocket costs, patients may choose not to fill the prescription (“primary” nonadherence), or split pills, skip doses, or delay refills (“secondary” non-adherence). 39
Every 10% increase in cost sharing decreases patients’ prescription drug spending
by 2 to 6%. 38 About 20-35% of cancer patients delay, forgo, or modify treatments
because of high out-of-pocket costs, affecting survival rates. 40 Higher out-of-pocket
drug costs (≥$30 per prescription) were associated with non-adherence in patients
taking oral anticancer drugs. 41-43 Chronically ill patients with monthly out-of-pocket
drug costs exceeding $100 were five times more likely to be non-adherent compared
to those with costs below $50. 44 A retrospective analysis of claims data from over
10,000 patients taking oral anticancer drugs, including imatinib, reported that 10% of
patients abandoned a newly prescribed oral cancer therapy due to higher patient
cost sharing. 33
Because non-adherence is a common issue, the National Comprehensive
Cancer Network (NCCN) CML guidelines recommend that when patients fail to
5

achieve optimal response at specific milestones as early as 3 months, physicians
should first assess patient TKI adherence before making any treatment adjustments.
10

Hematologic [normalization of peripheral blood counts], cytogenetic [decrease in

the number of Philadelphia-positive metaphases using bone marrow cytogenetics],
and molecular [decrease in the amount of BCR-ABL1 chimeric mRNA using
quantitative reverse transcriptase polymerase chain reaction, (QPCR)] responses
are measured to assess response to TKI treatment. 10
The goal of TKI therapy is to achieve a complete cytogenetic response
(CCyR) within 12 months of therapy initiation and to prevent disease progression to
accelerated or blast phase. 10 Hence, adherence to oral TKI therapy is crucial.
Adherent patients have better early responses and long-term outcomes with TKI
therapy. 13 Patients taking less than the prescribed medication or having treatment
gaps can fail to achieve CCyR, major molecular response (MMR), and complete
molecular response (CMR). 45 Even when patients miss as little as 10% of their daily
doses, amounting to as few as 3 days per month, they end up being less likely to
achieve MMR and more likely to lose cytogenetic response. 20,21,23,46
The success story of TKIs shows how effective but expensive novel
anticancer drugs will continue improving patient outcomes and expanding treatment
options, but patients and insurers are left to bear the increasing financial burden. 47
Despite their high cost, optimal use of TKIs has generated substantial health
improvements for CML patients, and can reduce the economic burden of CML for
6

insurers through decreased healthcare utilization. 47-50
Public Health Significance
Medication adherence, defined as “the process by which patients take their
medication as prescribed”, can be further divided into three quantifiable phases: (1)
initiation, (2) implementation, and (3) discontinuation. 51,52 Non-adherent patients
may delay or not initiate prescribed treatment (Phase 1), or compromise dosing
regimen or treatment duration (Phases 2 and 3). Medication adherence can be
affected by various inherently related factors that have critical therapeutic and health
implications. 52 Due to the high costs of TKIs, it is relevant to study if demand for
these drugs is affected by the cost-sharing burden imposed on patients by insurance
benefit design. Benefit-design decisions regarding anticancer drugs are particularly
challenging given the severity of the illnesses they treat, and insurers having to
balance the need to ensure patient access to a wide range of treatment options and
the need to control healthcare spending. 47
This dissertation adds to existing literature by studying CML patients
prescribed with TKIs using administrative claims data collected from individuals
insured through commercial employer health insurance plans. This study provides
insight into the impact of expected out-of-pocket spending on TKI initiation and
implementation (popularly termed as “adherence” and will subsequently be referred
to as such), the first two phases of “medication adherence” described previously that
are expected to bring the most benefit for adherent patients. Most medication
7

adherence studies evaluated use among patients who had initiated therapy, and not
so much on factors associated with therapy initiation itself. Two studies that
examined factors associated with TKI initiation and adherence were done in a
population of Medicare beneficiaries. 53,54 Another study that examined cost sharing
and TKI adherence in a commercially insured population used TKI claims from 2002
to 2011. 28 This dissertation used available data of five years from 2011 to 2015 that
enabled the study of the five TKIs currently approved for treatment of CML. In
addition, the study also comprehensively examined the association among out-ofpocket costs, TKI initiation (Phase 1) and adherence (Phase 2) with healthcare
utilization and costs. Based on literature review, this has not been attempted to
study the use of TKIs among CML patients.
Specific Aims
The research goal is to assess the relationship between patient prescription
cost sharing, tyrosine kinase inhibitors (TKIs) initiation and adherence, and
healthcare utilization and economic outcomes in a large group of commercially
insured patients with newly diagnosed chronic myeloid leukemia (CML).
Study One: How Patient Cost Sharing of Tyrosine Kinase Inhibitors Affects
Initiation, and Healthcare Utilization in Patients With Newly Diagnosed Chronic
Myeloid Leukemia
The specific aim in Journal Article 1 is to examine the association between
8

patient cost sharing with TKI initiation, and healthcare utilization and costs in
commercially insured patients with newly diagnosed CML.
Hypothesis 1 – Increased out-of-pocket costs are associated with patients delaying
initiation of TKI therapy.
Hypothesis 2 – Delayed TKI initiation is associated with more emergency room visits
and hospitalizations.
Hypothesis 3 – Delayed TKI initiation is associated with higher annual medical costs.
Study Two: Tyrosine Kinase Inhibitors and the Relationship to Adherence,
Costs and Healthcare Utilization in Commercially Insured Patients With Newly
Diagnosed Chronic Myeloid Leukemia
The specific aim in Journal Article 2 is to examine the association between
patient cost sharing with TKI adherence, and also the impact of TKI adherence on
subsequent healthcare utilization and costs in commercially insured patients with
newly diagnosed CML.
Hypothesis 1 – Increased out-of-pocket costs are associated with patients’ nonadherence to TKI therapy.
Hypothesis 2 – Higher TKI adherence is associated with fewer emergency room
visits and hospitalizations.
9

Hypothesis 3 – Higher TKI adherence is associated with lower annual medical costs.
Conceptual Framework
To identify predictors of TKI therapy initiation and adherence, this dissertation
examined a set of demographic and clinical characteristics selected with the
guidance of relevant conceptual models found in the literature. 30,55,56
Figure 1: Factors Influencing Delayed Initiation or Non-Adherence Due to Drug Cost

Thick black lines represent the ‘‘main effects’’ of financial pressures and regimen complexity on
initiation and adherence. Thin dashed lines represent the moderating effects of other domains on
patients’ response to cost pressures.
CML indicates chronic myeloid leukemia; OOP, out-of-pocket; TKI, tyrosine kinase inhibitor.
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The Andersen & Newman model 55 suggests that use of health services,
including prescription medications, is a function of patients’ predisposition to use
healthcare services, factors that enable or impede patients’ ability to use services,
and their illness level. Predisposing variables describe the propensity of individuals
to seek care, and include demographics such as age and sex. Enabling variables
describe the means available to individuals to use services, including geographic
region that could affect availability of medical care resources. Briesacher et al. 30 and
Piette et al.’s 56 models focus specifically on patients at risk for cost-related
medication non-adherence. They conceptualized that a patient’s decision to take
less medication than prescribed to cut costs can be predicted with risk factors that
could be categorized as main or secondary effects. Main effects include financial
pressures (e.g., drug cost sharing) and poly-pharmacy (e.g., number of concomitant
medications). Secondary effects refer to patients’ demographic and clinical
characteristics. Predictors of TKI non-adherence have been predominantly studied in
patients receiving imatinib 57 since imatinib was the first TKI approved, and has been
considered the standard of care for more than a decade 13,14.
Main Effects – Financial Pressures and Regimen Complexity
Variables for financial pressures include enrollment in prescription drug
coverage, TKI out-of-pocket costs, health plan type, and other out-of-pocket costs
paid by the patient for inpatient and outpatient services, and pharmacy medications
(excluding TKI medication). In the conceptual framework, TKI out-of-pocket costs
11

are hypothesized as the main effect that has a direct association with TKI initiation
and adherence.
Regimen complexity variables include the number of unique drug classes
filled as a measure of pill burden. Number of concomitant medications is a significant
predictor of adherence. 57 Adherence to cancer medications was found to decrease
with an increase in the number of medications (cancer and non-cancer) patients
were required to take 20,58-60, but one study found a higher concomitant of drug
burden related to higher rates of medication adherence 27.
Secondary Effects – Predisposing, Enabling and Illness Level Factors
A series of predisposing, enabling, and illness level factors are hypothesized
to explain patients’ initiation of and adherence to TKIs. Specifically, predisposing
variables include age and sex. There were inconsistent findings as to whether
younger or older age was related to better adherence 46,57,61, with studies identifying
older age as being associated with non-adherence 20, adherence as being
associated with increasing age 58,62, and younger age to be related to non-adherence
21,59

. Sex was also not consistently found to be associated with adherence 46,57,61,

with studies reporting females having higher rates of medication non-adherence 48 or
lower levels of adherence 58, and males as being related to higher rates of
medication non-adherence 20.
Enabling variables include patient’s relationship to subscriber, geographic
12

region, and year of CML diagnosis and TKI prescription. Illness level variables
include Deyo-Charlson comorbidity index as a measure of comorbidity burden 63,
Darkow CML Complexity Index score as a measure of the difficulty of managing
patient’s disease 48, the starting dose of the index TKI as a proxy for the phase of
CML disease 48,64, and an indicator variable for whether the patient had any dose
decrease of the TKI as a proxy for medication adverse effects 10. Patients who
reported higher cancer related complexity 48 had higher rates of medication nonadherence while patients with more cancer related complications also reported lower
levels of medication adherence 58. Imatinib dose is a significant predictor of
adherence. 57 Higher dosage or an increase in medication dosage was found to be
associated with higher levels of non-adherence. 20,21,48,50,59-61,65 Patients experiencing
adverse effects from the medication were more likely to be non-adherent.
21,27,46,57,61,66

DATA SOURCE
This study utilized 2011-2015 medical and pharmacy claims data collected
from the IBM® MarketScan® Commercial Database to provide a representative
sample of private health plans in the United States. 67 This database represents
active employees and their dependents, early retirees, and Consolidated Omnibus
Budget Reconciliation Act (COBRA) continuees insured by large employersponsored plans. This insurance claims data set contains information on over 200
million person-years of utilization, cost, and eligibility records, and it has been widely
13

used for statistical analysis because it encompasses 40 to 50 million privately
insured individuals each year, which is more than one quarter of the privately
insured US population 68. The database is considered to be nationally representative
of persons with employer-sponsored health insurance with respect to geography,
age, and gender. The data include monthly enrollment, inpatient and outpatient
medical claims, outpatient prescription drug claims, and reimbursed amounts paid by
the health plan and patient for services billed.
Human Subjects Considerations
The dissertation is determined to qualify for exempt status by The University
of Texas Health Science Center at Houston Committee for the Protection of Human
Subjects (HSC-SPH-17-0752) on August 18, 2017. All data were de-identified in
accordance with the Health Insurance Portability and Accountability Act (HIPAA)
requirements.
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Abstract
Background: High out-of-pocket costs may lead to disparities in the initiation of and
subsequent adherence to expensive medications. For newly diagnosed chronic
myeloid leukemia (CML) patients, early access to tyrosine kinase inhibitors (TKIs) is
a consistent predictor of adherence and optimal response.
Objective: The study examines the association between TKI out-of-pocket costs,
initiation, and response reflected in healthcare utilization and costs among patients
who initiated TKI within 12 months following first CML diagnosis.
Methods: Individuals aged 18 to 64 with an initial diagnosis of CML were identified
in the IBM® MarketScan® Commercial Database between 4/1/2011 and 12/31/2014.
The association between cost-sharing and TKI initiation was evaluated using a
multivariate logistic regression model applied to early (patients receiving therapy
within a month of diagnosis) and late initiators (1-12 months after diagnosis).
16

Healthcare utilization was compared using negative binomial regression models.
Healthcare cost differences between early and late initiators were estimated using
generalized linear models. All models were controlled for potential confounding
factors.
Results: The study sample consisted of 477 patients, 397 (83.2%) early initiators
and 80 (16.8%) late. Out-of-pocket costs for the initial 30-day supply of TKI
medications were not found to be a significant predictor of TKI initiation time. Early
initiators were much less likely to have all-cause hospitalizations (IRR=0.35;
p=0.02), or CML-specific hospitalizations (IRR=0.27; p<0.01). Over the 12-month
follow-up period, early initiators incurred $9,923 more in TKI pharmacy costs
(p<0.05), but late initiators incurred $7,582 more in medical costs, $218 more in nonTKI pharmacy costs, and $2,680 in total healthcare costs (p>0.05).
Conclusions: Patients with early TKI initiation had higher TKI pharmacy costs that
were more than offset by lower medical and non-TKI pharmacy costs, resulting in
lower overall total healthcare costs. Findings suggest that early TKI initiation may
reduce the risks of hospitalizations that could result in potential medical cost
savings.
Summary Bullets
What is already known about this subject
•

Chronic myeloid leukemia (CML) patients are required to take their daily dose
of oral tyrosine kinase inhibitors (TKIs) indefinitely for long-term survival.
17

•

Patients initiating anticancer drugs face high out-of-pocket costs because
prescription drug plans in the United States tend to have cost-sharing
mechanisms in order to control the high costs of these medications.

•

Despite the high costs of TKIs, CML patients gain significant health
improvements from their optimal use.

What this study adds
•

We used commercial insurance claims data to show the association between
TKI initiation, and healthcare utilization and costs in patients newly diagnosed
with CML.

•

Patients with early TKI initiation had lower risk of hospitalizations.

•

Patients with early TKI initiation had higher TKI pharmacy costs that were
more than offset by lower medical and non-TKI pharmacy costs, resulting in
lower overall total healthcare costs.

Introduction
Chronic myeloid leukemia (CML) accounts for 15% of all leukemias in adults.
1

In 2018, an estimated 8,430 people are expected to be diagnosed with CML in the

United States, and 1,090 people are expected to die from the disease. 2 CML is
usually diagnosed in the chronic phase, but if left untreated, the disease will
eventually progress to the advanced phase (accelerated or blast) in less than 5
years. 1,3 The National Comprehensive Cancer Network (NCCN) recommends
imatinib, dasatinib, and nilotinib as first-line tyrosine kinase inhibitor (TKI) therapy for
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newly diagnosed patients with chronic phase CML. 1 Imatinib was the first TKI
approved, and has been considered the standard of care for more than a decade
whereas second-generation TKIs, namely dasatinib and nilotinib, are highly effective
with the observed improvements in progression-free survival and overall survival in
newly diagnosed patients and those who fail imatinib. 4,5 Alternative second- and
third-generation TKIs, bosutinib and ponatinib, have also become available as
second line options. 1,4,5
Imatinib and other TKIs have revolutionized the management of CML, making
it possible for most CML patients treated with TKIs to experience near normal life
expectancy, especially if they were diagnosed before age 65. 6,7 Patients are
required to be adherent to their TKI therapy to achieve optimal response and prevent
disease progression. 8-10 In addition to adherence, newly diagnosed CML patients
who started imatinib within 6 months of diagnosis while in first chronic phase show
sustained responses and higher overall survival at a five-year follow-up. 11 Other
studies have shown that the cytogenetic and molecular responses, progression-free
survival, and event-free survival may be inferior in patients who start imatinib more
than 6 months after diagnosis. 12-15 Early prescribing has also been a consistent
predictor of adherence. 16 Hence, when indicated, a prescription for TKI therapy
should be provided promptly after CML diagnosis as studies found that time since
diagnosis for initiation of TKI therapy was associated with the CML patient’s level of
medication adherence. 16-18 Longer time lag between CML diagnosis and the fill of
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the first TKI prescription was associated with higher rates of non-adherence. 8,19 In
addition, studies show that non-adherence to treatment may be associated with high
annual healthcare costs, since it decreases treatment effectiveness. 20-22
All these studies underscore the importance of initial access to TKI for
patients newly diagnosed with CML who require prompt treatment. 23 Given the
expense of these targeted therapies, out-of-pocket costs for initiating therapy may
be high and could act as a barrier to starting treatment. In the United States, patients
may be subject to out-of-pocket payments of 20% of drug prices that could amount
to $20,000 - $30,000 annually. 24 Uninsured patients faced potential prices for
chemotherapy that were 2–43 times as much as the total Medicare-allowed amount
and 2–5 times as much as the private insurance–allowed amount. 25 Hence,
prescription coverage can become quite costly for cancer patients, and having a
prescription drug plan does not necessarily mean that it covers all costs for the
drugs needed. 26
In this study, we examined the association between patient cost sharing with
TKI initiation, and healthcare utilization and costs. Our study adds to literature in
three ways. First, the relationships among out-of-pocket costs, initiation, and
healthcare utilization and costs were studied within a single study, which based on
literature review is a more comprehensive approach than those that have been used
in the past. Second, this study measured actual healthcare utilization and costs in a
large group of commercially insured patients with newly diagnosed CML. Third, this
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study determined how delays in treatment impact healthcare utilization and overall
healthcare costs.
Methods
Data Source
This retrospective claims-based study was conducted using longitudinal
inpatient, outpatient, and pharmacy claims data from employer-based, commercially
insured group health plans in the United States, covering subscribers and
dependents up to age 65. We used the IBM® MarketScan® Commercial Database
from January 1, 2011 to December 31, 2015. The MarketScan database captured
person-specific clinical utilization, expenditures, and enrollment across inpatient,
outpatient, and prescription drug services. All data were de-identified in accordance
with the Health Insurance Portability and Accountability Act (HIPAA) requirements.
Sample Selection
We applied several selection criteria to capture a main sample of patients with
newly diagnosed CML. Patients were included if they had at least 1 inpatient or 2
outpatient claims (at least 30 days apart) with a diagnosis of CML between April 1,
2011, and December 31, 2014 (the first of which represents the “index claim”). CML
diagnosis is defined using International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] code for chronic myeloid leukemia (205.1X), or
International Classification of Diseases, Tenth Revision, Clinical Modification [ICD10-CM] code for chronic myeloid leukemia (C92.1X).
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Patients were excluded if they were a) younger than age 18 years at index
claim date, or turned 65 during the study period, and had b) no continuous
enrollment in the health plan in the 3 months before and 12 months after the index
claim; c) no drug benefit; d) any claim for a TKI preceding CML diagnosis; e) no
claim for a molecular oncogene diagnostic test (during the 30 days before or the 30
days after the index claim); f) not initiate a TKI within 12 months of CML diagnosis;
and g) no continuous enrollment in the health plan and drug benefit during the 12
months after TKI initiation.
Study Variables
Measure for TKI out-of-pocket costs. The mean out-of-pocket costs were
calculated for the first 30-day supply of TKI medication. Out-of-pocket costs were
defined as the sum of the copayments, coinsurance, and deductibles paid by the
patient at the time that the first TKI prescription was filled. Out-of-pocket cost
amounts for 60- or 90-day prescriptions were adjusted to 30-day amounts. The
mean out-of-pocket costs per patient were used, along with other patient
characteristics, to predict TKI initiation.
Measure for TKI initiation. The variable measured the time to TKI initiation, defined
as the number of months elapsed between the index claim date (first CML diagnosis
claim during the study period) and the date that the first TKI prescription was filled
during the 12-month post-index period. All TKIs approved for CML and available
during the 2011 to 2015 study period (imatinib [Gleevec], dasatinib [Sprycel],
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nilotinib [Tasigna], bosutinib [Bosulif], and ponatinib [Iclusig]) were included in the
measure definition.
Clinical benefits are most likely to occur when CML patients initiate TKI within
6 months after diagnosis. 11-15 For our study, we used the threshold of one month
since patients are expected to begin treatment as soon as they are diagnosed for
optimal response. 1 Patients were classified as early initiators of TKI if they had a
first claim for a TKI prescription within the first month of CML diagnosis. They were
considered to have delayed TKI initiation if their first claim for a TKI prescription
occurred after a month of diagnosis and before the end of the 12-month post-index
period.
Outcomes
Annual healthcare utilization. We assessed healthcare utilization during the 12month follow-up period from TKI initiation. Five distinct utilization measures were
assessed: (1) number of outpatient physician visits; (2) number of emergency room
[ER] visits; (3) number of all-cause hospitalizations; (4) number of CML-specific
hospitalizations (identified as any inpatient admission with an ICD-9-CM or ICD-10CM code for CML as the primary or secondary diagnosis); and (5) number of
prescriptions.
Annual healthcare costs. We examined healthcare costs during the 12-month
follow-up period from TKI initiation. Costs are reflected in the allowed amount, which
23

is equal to the sum of plan paid, Coordination of Benefits and Other Savings (COB),
and patient out-of-pocket costs, including copayments, coinsurance, and
deductibles. Four distinct cost variables were reported: (1) medical costs; (2) TKI
pharmacy costs; (3) non-TKI pharmacy costs; and (4) total all-cause healthcare
costs – representing aggregated medical and pharmacy costs.
Medical costs included costs associated with any inpatient or outpatient
encounter during the 12-month follow-up period. TKI pharmacy costs included costs
associated with pharmacy claims for imatinib, dasatinib, nilotinib, bosutinib, and
ponatinib during the 12-month follow-up period. Non-TKI pharmacy costs covered
costs associated with any other pharmacy claims not included in the TKI pharmacy
related cost calculation.
Costs ($US) were converted to 2015 values using the medical component of
the Consumer Price Index.
Covariates
Patient characteristics were limited to those variables available in the
MarketScan database. We reported demographic characteristics as of the index
claim date, such as patient age, sex, year of the index claim, health plan type
(comprehensive, preferred provider organization [PPO], point-of-service [POS],
consumer-driven health plan/high deductible health plan [CDHP/HDHP], exclusive
provider organization [EPO], health maintenance organization [HMO]), region of
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residence (Northeast, North Central, South, West), and the patient’s relationship to
subscriber (subscriber versus spouse or dependent).
We identified clinical characteristics using all available medical and pharmacy
claims for study patients in the 3-month pre-index period. These included DeyoCharlson comorbidity index as a measure of comorbidity burden 27, the number of
unique drug classes filled as a measure of pill burden, and Darkow CML Complexity
Index score (categorized as usual, moderate, or high, using reported diagnoses of
associated complications, comorbidities, or adverse events) as a measure of the
difficulty of managing patient’s disease 22. The starting dose of the index TKI
medication is used as a proxy for the phase of CML disease. 22,28 This dose was
calculated as the strength of TKI dispensed multiplied by the quantity filled, divided
by the days’ supply on the pharmacy claim. For imatinib, the starting dose was
categorized as ≤400mg [i.e., the typical starting dose for chronic phase CML] or
≥600mg [i.e., the typical starting dose for accelerated phase or blast crisis]. 29 For
dasatinib, the starting dose was categorized as ≤100mg [i.e., the typical starting
dose for chronic phase CML] or ≥140mg [i.e., the typical starting dose for advanced
phase]. 30 For nilotinib, the starting dose was categorized as ≤600mg [i.e., the typical
starting dose for chronic phase CML] or ≥800mg [i.e., the typical starting dose for
accelerated phase]. 31 For bosutinib, the starting dose was categorized as ≤500mg
[i.e., the typical starting dose for chronic, accelerated, or blast phase CML in patients
resistant to or intolerant to other therapies, including imatinib]. 32 For ponatinib, the
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starting dose was categorized as ≤45mg [i.e., the typical starting dose for chronic,
accelerated, or blast phase CML in patients for whom no other TKI therapy is
indicated]. 33
An indicator variable for whether the patient was adherent to TKI during the
12-month follow-up was used. We estimated the patient’s adherence to TKI using
the proportion of days covered (PDC). 34 Patients were classified as adherent to TKIs
if they have PDC of at least 80% when they are most likely to achieve clinical
benefits from their treatment. 8-10 We used an indicator variable for whether the
patient had any TKI dose decrease as a proxy for TKI adverse events during the 12month follow-up period because TKI toxicities are managed by decreasing the initial
dose prescribed. 1 The other control variable was mean other out-of-pocket costs
paid by the patient for inpatient and outpatient services, and non-TKI pharmacy
medications for the entire 12-month follow-up period.
Statistical Analyses
We conducted statistical comparisons between the characteristics of patients
who initiated TKI therapy within 1 month (early initiators) and 1-12 months (late
initiators) of CML diagnosis using the Wilcoxon-Mann-Whitney test for continuous
variables and Pearson’s chi-squared test or the Fisher’s exact test (for sparse data
with frequency of five or less) for categorical variables.
TKI initiation. We used a multivariate logistic regression model with robust standard
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error estimates to calculate the odds of initiating TKI early, controlling for potential
confounding factors. We determined the adjusted risk ratio (ARR) and adjusted risk
difference (ARD) instead of odds ratio because TKI initiation was considered to be a
common event. 35 The ARR is the ratio of the mean predicted probabilities, 36 and
represents the probability of TKI initiation for each TKI out-of-pocket cost category
after controlling for potential confounding factors. The ARD is the difference of the
mean predicted probabilities, 36 and constitutes differences in the absolute risk of
initiation.
Healthcare utilization and costs. Healthcare utilization was compared between the
early and late initiator cohorts using unadjusted and adjusted incidence rate ratios
(IRRs). Adjusted IRRs controlled for potential confounding factors and were
estimated using multivariate negative binomial regression models 37. No offset
variable is needed because all outcome variables were observed for a full year.
Unadjusted and adjusted cost differences between the early and late initiator
cohorts were estimated using multivariate generalized linear models with a gamma
distribution and a log link, 22 controlling for potential confounding factors.
All multivariate regression analyses controlled for the same set of potential
confounding factors relevant for the respective study. To study the association
between TKI out-of-pocket costs and TKI initiation, the covariates used included
patient age, sex, patient’s relationship to subscriber, health plan type, region of
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residence, CML year of diagnosis, CML phase, type of TKI medication, CML
complexity, Deyo-Charlson comorbidity index, and number of concomitant
medications. In the estimation of healthcare utilization and costs, the covariates
used included an indicator variable of whether the patient is adherent, patient age,
sex, patient’s relationship to subscriber, health plan type, region of residence, TKI
year of initiation, CML phase, type of TKI medication, any TKI dose decrease, CML
complexity, Deyo-Charlson comorbidity index, number of concomitant medications,
and other out-of-pocket healthcare costs.
All statistical analyses were performed using STATA version 15 (StataCorp
LP, College Station, Texas). Statistical significance was assumed at p-values less
than 0.05. The study protocol was considered exempt by The University of Texas
Health Science Center at Houston Institutional Review Board.
Results
Patient characteristics
There were 477 unique patients newly diagnosed with CML between April 1,
2011 and December 31, 2014, who satisfied the selection criteria for inclusion into
our study, where 397 (83.2%) patients were classified as early initiators for initiating
TKI within a month from first CML diagnosis, and 80 (16.8%) late initiators for
initiating TKI within 1 to 12 months from first CML diagnosis (Figure 2).
Patient characteristics were similar in the early and late TKI initiator cohorts
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(Table 1). The mean age was approximately 49 years in the early initiator cohort,
and 48 years in the late initiator cohort, although the difference was not statistically
significant (p=0.32). Most patients were aged 50-59 years for both early and late
initiators. The early initiator cohort contained a significantly (p=0.04) higher
percentage of males than the late initiator cohort (56.2% versus 43.8%). The
majority of patients in both cohorts were enrolled in the preferred provider
organization (PPO) health plan type and lived in the south, which is consistent with
the inherent skewness of the MarketScan data set for these groups. Most patients in
the early initiator cohort used dasatinib as their index treatment (40.0%), whereas
most late initiators used imatinib (43.8%) (p=0.01).
Statistically significant differences (i.e., p<0.05) were not observed for CML
phase, CML complexity, comorbid conditions, or concomitant medications at
baseline. Most patients were in the chronic phase of CML; 94.5% of early initiators
and 91.3% of late initiators respectively, and have usual CML complexity; 61.7% and
67.5% respectively. The 10 most prevalent comorbidities found among the study
cohorts are reported in Table 1.
The late initiator cohort has slightly higher mean out-of-pocket costs for the
first 30-day supply of TKI medication ($231 vs. $190; p<0.01). Costs varied
substantially among individuals in our sample, with 8.4% of the sample paying more
than $400, double the average amount, for the first 30-day supply of TKI. On
average, copayments accounted for approximately 81.4% of the initial out-of-pocket
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costs for the first 30-day supply of TKI medication, while coinsurance and
deductibles accounted for 13.6% and 5.0% respectively. Without taking into account
patients who had no TKI out-of-pocket costs, most of the early initiators paid $50 or
less (43.3%), whereas a majority of the late initiators incurred more than $100
(33.8%) for their first month supply of TKI medication.
In the unadjusted analysis, TKI initiation was associated with out-of-pocket
costs for first TKI supply, patient sex, and index treatment.
TKI initiation
As shown in Table 2, the only factor significantly associated with later
treatment initiation was being male (ARR, 0.62; 95% CI, 0.41 to 0.95).
Healthcare utilization and costs
Late initiator patients were observed to have greater healthcare utilization
compared to early initiator patients, particularly utilization related to outpatient
physician visits, emergency room visits, and hospitalizations (Table 3). On an
unadjusted basis, early initiator patients were less likely to have all-cause
hospitalizations (IRR=0.29, p<0.01); and CML-specific hospitalizations (IRR=0.19,
p<0.01). After adjusting for potential confounding factors, early initiators were much
less likely to have all-cause hospitalizations (IRR=0.35; p=0.02), or CML-specific
hospitalizations (IRR=0.27; p<0.01). Outpatient visits were the most frequently used
health service in both study cohorts (early initiators = 17.5 visits, late initiators = 17.8
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visits), but unadjusted and adjusted utilization did not vary between these patients
(p>0.05).
The only significant difference found among the cost components of the total
annual all-cause healthcare costs between the two study cohorts was for TKI
pharmacy costs (Table 4). We found that early initiators incurred higher TKI
pharmacy costs by $9,923 (p<0.05). Late initiators, on the other hand, incurred
$7,582 more in medical costs, $218 more in non-TKI pharmacy costs, and $2,680
more in total all-cause healthcare costs (all p>0.05).
Discussion
Most patients newly diagnosed with CML initiated TKI treatment within a
month of diagnosis with no significant association with out-of-pocket costs for the
first 30-day supply of TKI medication. This finding is in contrast with other
retrospective cohort studies that have found the association between high cost
sharing with reduced and/or delayed initiation of TKIs. 23,38-40 These studies,
however, compared the effect of cost sharing for Medicare patients between those
who faced nominal cost sharing of ≤$5 throughout the year if they quality for full lowincome (LIS) subsidies, and fee-for-service non-LIS patients.
To the best of our knowledge, this is the first study to research the association
between patient cost sharing and TKI initiation in a population of commercially
insured patients newly diagnosed with CML. In our study cohort, 14.5% had no out31

of-pocket costs for their first month supply of TKI, and the majority of patients
(41.3%) incurred costs of $50 or less. Out-of-pocket costs for the first 30-day supply
of TKI medication averaged $198; median out-of-pocket costs were $42 (range, $0
to $9,443). Costs differed substantially among individuals in our sample, with 8.4%
paying twice the estimated average costs for the first 30-day supply of TKI
medications.
Available funding resources for commercially insured patients may have
helped in enabling them to get initiated on TKIs early after diagnosis of CML. Cancer
patients can explore resources such as the Leukemia & Lymphoma Society (LLS)
Co-pay Assistance Program; patient assistance or prescription assistance programs,
sponsored by major pharmaceutical manufacturers; or prescription savings
programs to help finance treatment. 26 However, when these programs are used, the
costs are not reflected in the claims data at all.
Further research would be required to determine if there is any association
between the continuous monthly out-of-pocket costs that patients incur for TKI
medications and their adherence. This is especially pertinent as patient assistance
programs are subject to availability of funds as well as the program maximum that is
imposed. For example, the LLS Co-pay Assistance Program for CML provides
$2,000. 41 The Universal Co-pay Card offered by Novartis Pharmaceuticals
Corporation for Gleevec and Tasigna requires that the patient be responsible for up
to the first $25 with the remaining co-pay or coinsurance paid for by the program
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until the yearly maximum of $15,000 after which the patient is responsible for the
difference. 42
Patients who initiated TKI early have correspondingly higher TKI pharmacy
costs. TKIs usually account for the majority of total pharmacy costs. 43 Our findings
on total all-cause healthcare costs are consistent with reports using similar claimsbased methodology among insured patients. 28 CML is a chronic disease requiring
routine follow-up. As expected, outpatient visits were the most used health care, and
inpatient and emergency room visits were low in both patient cohorts. These
healthcare utilization patterns were consistent with other reports in the literature.
21,22,28

The main finding is that patients who delayed initiation of TKI experienced

higher levels of healthcare utilization. Most notably, they were much more likely to
have more frequent adjusted all-cause hospitalizations, and adjusted CML-specific
hospitalizations (all p<0.05).
Our findings have important implications. Oral anticancer medications are
typically covered under a pharmacy benefit with substantial out-of-pocket costs due
at the time the medication is obtained at the pharmacy. 39 High out-of-pocket costs
for TKI medications are significantly associated with delayed access and nonadherence. 38,39,44 Clinical guidelines recommend initiating a TKI immediately after a
diagnosis of CML, and patients using these therapies are expected to take them for
a long period of time. 45 Low adherence to TKI therapy can decrease response to
treatment, which can result in patients requiring stem-cell transplantation, worse
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clinical outcomes, and potentially shorter life expectancy. 46 Total healthcare costs
are higher for episodes of TKI treatment failures than those of ongoing treatment
with the costs increasing with each sequential line of TKI treatment failure. 47,48
This underscores the importance of having doctors or social workers talk with
newly diagnosed CML patients about how to finance treatment and explore
resources to help with their expenses. Patients should be made aware that financial
support is not only available for low-income individuals. For instance, to be eligible
for the LLS Co-pay Assistance Program, one has to be at or below 500% of the U.S.
federal poverty guidelines as adjusted by the Cost of Living Index. 41 A single person
is eligible if they have a household income at or below $60,700, whereas a
household with 4 people is eligible with an income at or below $125,500. 41
In addition, doctors and pharmacists should focus on assessing the
“treatment value” of different TKI therapies in relation to benefits versus cost; for
instance, prescribing lower dose dasatinib, which has at least equivalent efficacy
compared to second generation TKIs but at a significant lower cost comparable to
generic imatinib. 45 Efforts to lower drug prices and subsequently, the out-of-pocket
costs for TKI medications could significantly improve adherence, and overall health
and economic outcomes among CML patients. Future research should focus on
assessing barriers to timely access to healthcare for early diagnosis of CML and
optimal TKI adherence to advance the understanding of and eliminate health
disparities in cancer.
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Limitations
Several study limitations should be noted. Additional clinical and
socioeconomic variables that were not available in our claims data raised the
potential for unobserved confounding. We sought to minimize the limitations of
administrative claims data by employing multivariate regressions to control for a
variety of sociodemographic and clinical characteristics that could influence
treatment decisions. Other common limitations such as missing data and errors in
claims coding may also apply in this study. Nonetheless, claims data provide a valid,
big sample source of actual practice data. 43
The use of insurance claims data included information on filled prescriptions
only, and thus, we are unable to determine whether our large group of non-initiators
did not receive a prescription, or whether they received a prescription but did not fill
it. It is also possible that some patients who were classified as not initiating
treatment, or as delaying initiation, may have been receiving medication via other
means that would not have resulted in a prescription claim. In some cases, patients
may also have supplemental cost-sharing help from patient assistance programs,
which would result in our results underestimating the true adverse impact of high
cost sharing.
This analysis also only examined patients under age 65. All patients in the
study were commercially insured in a plan that offered prescription coverage and are
likely healthier and younger than the general population of CML patients. However,
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our findings may well be applicable to CML patients aged 65 years and older despite
excluding Medicare beneficiaries, who constitute about half of all patients with CML
at diagnosis. 21
The 5-year study period of 2011-2015 allows for a good observation of CML
patients receiving imatinib, dasatinib, and nilotinib, which were the first three TKIs
approved by the US Food and Drug Administration (FDA) for CML treatment in
2001, 2006, and 2007 respectively. 49 This resulted in our study having a negligible
number of CML patients on bosutinib and ponatinib, two TKIs that were approved by
the FDA for CML treatment in 2012. 49
Conclusions
Our study suggests that patients with early TKI initiation were at lower risk of
adverse events such as hospitalizations, resulting in lower medical costs. These
would offset their higher TKI pharmacy costs leading to lower overall total healthcare
costs.
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Table 1: Sample Characteristics by TKI Initiation Time from First CML Diagnosis
Patients who initiated TKI therapy
In 1 month or less
from first CML
diagnosis

Within 1-12
months from first
CML diagnosis

(n = 397)

(n = 80)

49.10±10.49
[51]

47.59±11.35
[49.5]

p-value

Demographic characteristics
Age at the index date, years,
mean±SD [median]
Age group, years, n

0.35

18 – 39

71 (17.9%)

21 (26.3%)

40 – 49

101 (25.4%)

19 (23.8%)

50 – 59

166 (41.8%)

28 (35.0%)

60 – 64

59 (14.9%)

12 (15.0%)

223 (56.2%)

35 (43.8%)

Male, n

0.32

Patient’s relationship to
subscriber, n

0.04

b

0.80

Subscriber

264 (66.5%)

52 (65.0%)

Spouse or dependent

133 (33.5%)

28 (35.0%)

Health plan type, n

0.64

Group: Comprehensive /
Preferred provider
organization / Point-ofservice / Exclusive
provider organization

292 (73.6%)

56 (70.0%)

Consumer-driven health
plan / high deductible
health plan

40 (10.1%)

11 (13.8%)

Health maintenance
organization

37 (9.3%)

9 (11.3%)
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a

Patients who initiated TKI therapy

Missing / Unknown

In 1 month or less
from first CML
diagnosis

Within 1-12
months from first
CML diagnosis

(n = 397)

(n = 80)

28 (7.1%)

4 (5.0%)

Region of residence, n
88 (22.2%)

11 (13.8%)

North Central

83 (20.9%)

14 (17.5%)

South

152 (38.3%)

40 (50.0%)

West

64 (16.1%)

13 (16.3%)

Unknown

10 (2.5%)

2 (2.5%)

Index year, n

0.29

2011

101 (25.4%)

26 (32.5%)

2012

111 (28.0%)

26 (32.5%)

2013

95 (23.9%)

14 (17.5%)

2014

90 (22.7%)

14 (17.5%)

12.05±7.75
[11]

85.68 ±63.08
[68.5]

Index treatment, n

<0.001

0.01

Imatinib
Started on ≤400 mg/day

138 (34.8%)

35 (43.8%)

Started on ≥600 mg/day

9 (2.3%)

0

157 (39.5%)

21 (26.3%)

Dasatinib
Started on ≤100 mg/day

a

0.29

Northeast

Time to drug index date from
diagnosis date, days, mean±SD
[median]

p-value
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b

b

Patients who initiated TKI therapy
In 1 month or less
from first CML
diagnosis

Within 1-12
months from first
CML diagnosis

(n = 397)

(n = 80)

2 (0.5%)

0

Started on ≤600 mg/day

80 (20.2%)

17 (21.3%)

Started on ≥800 mg/day

11 (2.8%)

5 (6.3%)

0

1 (1.2%)

0

1 (1.2%)

375 (94.5%)

73 (91.3%)

Started on ≥140 mg/day

p-value

Nilotinib

Bosutinib
Started on ≤500mg/day
Ponatinib
Started on ≤45mg/day
CML chronic phase, n
Darkow CML Complexity Index,
n

0.55

Usual

245 (61.7%)

54 (67.5%)

Moderate

96 (24.2%)

15 (18.8%)

High

56 (14.1%)

11 (13.8%)

2.38±0.96 [2]

2.59±1.47 [2]

Deyo-Charlson comorbidity
index, mean±SD [median]

0.27

10 most prevalent
comorbidities, n

0.75
-

Diabetes

42 (10.6%)

8 (10.0%)

Chronic obstructive
pulmonary

23 (5.8%)

4 (5.0%)

Cerebrovascular

6 (1.5%)

1 (1.3%)

Rheumatoid disease

6 (1.5%)

1 (1.3%)
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c

a

Patients who initiated TKI therapy

p-value

In 1 month or less
from first CML
diagnosis

Within 1-12
months from first
CML diagnosis

(n = 397)

(n = 80)

Acute myocardial

6 (1.5%)

0

Metastatic cancer

5 (1.3%)

4 (5.0%)

Renal

5 (1.3%)

1 (1.3%)

Congestive heart

4 (1.0%)

2 (2.5%)

Peripheral vascular

4 (1.0%)

1 (1.3%)

Hemiplegia / paraplegia

2 (0.5%)

0

3.79±3.19 [3]

3.41±3.31 [3]

0.19

189.37±683.14
[36.79]

230.24±645.48
[56.06]

<0.01

Concomitant medications /
Number of unique drug
classes, mean±SD [median]
Out-of-pocket costs for first 30
days' supply of TKI medication,
$, mean±SD [median]
Out-of-pocket costs group, n

0.04

$0

60 (15.1%)

9 (11.2%)

>$0 – $50

172 (43.3%)

25 (31.2%)

>$50 – $100

84 (21.2%)

19 (23.8%)

>$100

81 (20.4%)

27 (33.8%)

a

a

b

b

Comparing the differences between patients who initiated TKI therapy ≤ 1 month and 1-12 months.
Continuous variables were compared using the Wilcoxon-Mann-Whitney test. Categorical variables
were compared using Pearson’s chi-squared test or the Fisher’s exact test if one or more cells have
an expected frequency of five or less.
b
Significant at the 5% level.
c
P-values not presented because data is too sparse.
CML indicates chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.
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Table 2: Adjusted Risk Ratio (ARR) and Adjusted Risk Difference (ARD) of TKI
Initiation Among Individuals With CML (n=477)
Characteristics

ARR

a

95% CI

ARD

a

95% CI

Mean out-of-pocket costs
for first 30-day supply of TKI
medication
$0

Reference

Reference

>$0 – $50

1.06

0.53 to 2.11

0.01

-0.11 to 0.13

>$50 – $100

1.30

0.65 to 2.60

0.05

-0.09 to 0.18

>$100

1.64

0.86 to 3.12

0.09

-0.04 to 0.22

Age at the index date, years
18 – 39

Reference

40 – 49

0.73

0.39 to 1.37

-0.05

-0.14 to 0.04

50 – 59

0.69

0.40 to 1.18

-0.06

-0.14 to 0.02

60 – 64

0.84

0.42 to 1.67

-0.03

-0.13 to 0.07

0.62

0.41 to 0.95

-0.08

-0.15 to -0.01

1.03

0.66 to 1.60

0.00

-0.07 to 0.08

Male versus female

b

Subscriber (yes versus no)

Reference

Health plan type
Group: Comprehensive /
Preferred provider
organization / Point-ofservice / Exclusive provider
organization

Reference

Reference

Consumer-driven health
plan / high deductible
health plan

1.46

0.80 to 2.67

0.07

-0.06 to 0.20

Health maintenance
organization

1.19

0.61 to 2.33

0.03

-0.10 to 0.16

Missing / Unknown

0.98

0.39 to 2.49

-0.00

-0.15 to 0.15
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Characteristics

ARR

a

95% CI

ARD

a

95% CI

Region of residence
South

Reference

Reference

Northeast

0.57

0.28 to 1.13

-0.08

-0.16 to 0.00

North Central

0.71

0.40 to 1.25

-0.05

-0.13 to 0.03

West

0.87

0.50 to 1.53

-0.02

-0.11 to 0.06

Unknown

0.86

0.21 to 3.46

-0.03

-0.22 to 0.18

Index year
2011

Reference

Reference

2012

0.88

0.53 to 1.47

-0.02

-0.10 to 0.06

2013

0.60

0.32 to 1.13

-0.07

-0.15 to 0.00

2014

0.68

0.37 to 1.24

-0.06

-0.14 to 0.02

Index treatment
Imatinib

Reference

Reference

Dasatinib

0.66

0.40 to 1.10

-0.06

-0.14 to 0.01

Nilotinib

1.16

0.71 to 1.90

0.03

-0.06 to 0.11

0.82

0.36 to 1.87

-0.04

-0.20 to 0.13

Chronic phase CML (yes
versus no)
Darkow CML Complexity
Index
Usual

Reference

Reference

Moderate

0.76

0.45 to 1.26

-0.04

-0.11 to 0.03

High

1.00

0.56 to 1.78

0.00

-0.09 to 0.10

Deyo-Charlson comorbidity
c
index

1.24

1.00 to 1.54

0.02

0.01 to 0.04

Concomitant medications /
Number of unique drug

0.98

0.91 to 1.04

-0.00

-0.02 to 0.01
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Characteristics
classes

ARR

a

95% CI

ARD

a

95% CI

c

a

ARR and ARD were determined using a multivariate logistic regression model with robust standard
error estimates.
b
Significant at the 5% level.
c
Treated as continuous.
ARD indicates adjusted risk difference; ARR, adjusted risk ratio; CI, confidence interval; CML, chronic
myeloid leukemia; TKI, tyrosine kinase inhibitor.
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Table 3: Comparison of Healthcare Utilization Between Early and Late TKI Initiator
Patients
Average Annual Utilization
(mean±SD)

Unadjusted

Adjusted

Patients who initiated TKI
therapy
In 1 month
or less from
first CML
diagnosis

Within 1-12
months
from first
CML
diagnosis

IRR

a

p-value

IRR

a

p-value

(n = 397)
(n = 80)
Outpatient
physician visits

17.49±9.81

17.80±14.89

0.98

0.86

1.01

0.89

Emergency
room (ER)
visits

0.54±1.98

0.79±2.11

0.69

0.29

0.73

0.27

All-cause
hospitalizations

0.08±0.45

0.26±0.82

0.29

<0.01

b

0.35

0.02

CML-specific
hospitalizations

0.04±0.24

0.21±0.77

0.19

<0.01

b

0.27

<0.01

Number of
prescriptions
(all drugs)

34.35±27.22

37.60±31.81

0.91

0.38

0.88

0.09

Number of TKI
prescriptions

10.23±3.41

9.79±4.48

1.05

0.41

0.99

0.77

Number of nonTKI
prescriptions

24.12±26.54

27.81±30.60

0.87

0.29

0.81

0.06

a

b

b

An IRR >1 indicates that early initiator patients had higher incidence of incurring medical services
compared to late initiator patients. IRR were estimated using multivariate negative binomial
regressions.
b
Significant at the 5% level.
CML indicates chronic myeloid leukemia; IRR, incidence rate ratio; TKI, tyrosine kinase inhibitor.
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Table 4: Comparison of Healthcare Costs Between Early and Late TKI Initiator
Patients
Average Annual Costs,$ (mean±SD)

Unadjusted

Adjusted

Patients who initiated TKI therapy
In 1 month or less from
first CML diagnosis

Within 1-12 months from
first CML diagnosis

Cost
a
Difference

(n = 397) [A]

(n = 80) [B]

[A] – [B]

pvalue

b

Medical
costs

18,022.82±47,196.26

37,385.61±102,911.10

-19,362.79

0.03

TKI
pharmacy
costs

100,261.80±32,276.67

85,516.64±37,864.63

14,745.16

<0.01

Non-TKI
pharmacy
costs

2,580.74±6,031.22

2,644.48±4,655.23

-63.74

Total allcause
healthcare
costs

120,865.40± 57,195.23

125,546.70±108,251.90

-4,681.30

a

Cost
a
Difference
(beta
coefficient)

pvalue

-7,581.78
(-.29)

0.22

9,922.02
(.11)

<0.05

0.92

-217.17
(-.05)

0.80

0.70

-2,679.20
(-.02)

0.79

b

Cost differences <0 indicate that late initiators incurred higher healthcare costs. Cost differences
were estimated using multivariate generalized linear models with a gamma distribution and a log link.
b
Significant at the 5% level.
TKI indicates tyrosine kinase inhibitor.
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b

Figure 2: Study Cohort Selection and Subject Exclusion

Patients with at least 1 inpatient or 2 outpatient
claims with CML diagnosis (ICD-9-CM code 205.1X
or ICD-10-CM code C92.1X) between January 1,
2011, and December 31, 2015
(n = 14,519)
Exclude patients who did not have continuous
health plan enrollment for 3 months before
and 12 months after first CML diagnosis,
“index claim”
(n = 10,882)
Exclude patients with no drug benefit
(n = 112)
Exclude patients younger than age 18 years
or who turned 65 during the study period
(n = 171)
Exclude patients who had any TKI claim
preceding index claim date
(n = 555)
Exclude patients without a claim for a
molecular oncogene diagnostic test (during
the 30 days before or the 30 days after the
index claim date)
(n = 1,271)
Exclude patients who did not initiate TKI
within 1 year from first CML diagnosis
(n = 908)
Exclude patients who did not have continuous
health plan and drug benefit enrollment for 12
months after TKI initiation
(n = 143)
Patients who initiated TKI
in ≤1 month from first CML
diagnosis
(n = 397)

Patients who initiated TKI
within 1-12 months from
first CML diagnosis
(n = 80)

Final cohort for analysis
(n = 477)

57

JOURNAL ARTICLE 2
Tyrosine Kinase Inhibitors and the Relationship to Adherence, Costs and
Healthcare Utilization in Commercially Insured Patients With Newly Diagnosed
Chronic Myeloid Leukemia: A Retrospective Claims-Based Study
Current Medical Research and Opinion
Authorship List: Hsiao Ling Phuar, MSc, BPharm; Charles E. Begley, PhD;
Wenyaw Chan, PhD; and Trudy Millard Krause, DrPH, MBA
Author Affiliations: The University of Texas Health Science Center at Houston
School of Public Health (HLP, CEB, WC, TMK), Houston, TX.
Address for correspondence: Hsiao Ling Phuar, MSc, BPharm, PhD Candidate,
Department of Management, Policy, and Community Health, The University of Texas
Health Science Center at Houston School of Public Health, 1200 Pressler Street,
Houston, TX 77030. E-mail: Hsiao.Ling.Phuar@uth.tmc.edu
Abstract
Background: For chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitor
(TKI) adherence is crucial in achieving optimal response. The study examines the
association among TKI out-of-pocket costs, adherence, and healthcare costs and
utilization in a large group of commercially insured CML patients.
Methods: CML patients aged 18 to 64 were identified using IBM® MarketScan®
Commercial Database between 4/1/2011 and 12/31/2014. Patients were required to
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be continuously enrolled 3 months before and 12 months following TKI (imatinib,
dasatinib, nilotinib, bosutinib, or ponatinib) initiation. TKI adherence is estimated
using the proportion of days covered (PDC), defined as the percentage of the
proportion of days covered by the prescription fill during the 12-month study period
(adherent patients have PDC≥80%). Healthcare cost differences between adherent
and non-adherent patients were estimated using generalized linear models.
Healthcare utilization was compared using negative binomial regression models. All
models were controlled for potential confounding factors.
Results: The study sample consisted of 867 patients, where 357 (41.2%) patients
were classified as adherent. Patients with higher TKI out-of-pocket costs (≥75th
percentile in the distribution of costs) for a 30-day supply have lower predicted PDC
by 2.4% (p<0.001). Over the study period, non-adherent patients incurred $10,985
more in medical costs (p<0.001), and $1,642 more in non-TKI pharmacy costs
(p<0.01). Adherent patients incurred $29,061 more in TKI pharmacy costs (p<0.001)
that resulted in $19,222 more in overall total healthcare cost (p<0.001). Adherent
patients, however, were estimated to be less likely to have all-cause hospitalizations
(IRR=0.32; p<0.001), or CML-specific hospitalizations (IRR=0.30; p<0.01).
Conclusions: CML patients with lower TKI out-of-pocket costs were more adherent
and experienced fewer hospitalizations, resulting in medical service cost savings.
These lower medical costs, however, were more than offset by higher TKI
medication costs observed during the first year of TKI therapy.
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Keywords: Adherence – Chronic myeloid leukemia – Cost – Tyrosine kinase
inhibitor – Utilization
Introduction
In the United States, cancer comes in second among all causes of death after
heart disease. 1 However, more Americans are surviving cancer over a 10-year
period with current statistics showing approximately 15.5 million cancer survivors in
January 2016 2 in comparison to 11.4 million in January 2006, 3 reflecting
improvements in treatment and earlier diagnosis 2. Much anticancer drug
development has focused on targeted therapies. 4 The use of targeted therapies in
cancer grew from 11% in 2003 to 46% in 2013 5 because additional indications for
such drugs approved in the early 2000’s led to their increased uptake, affecting the
use of traditional cytotoxic and hormonal therapies 6. Tyrosine kinase inhibitors
(TKIs) are considered to be the most successful class of targeted cancer therapies,
exceeding all survival expectations. 7
Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. 8 CML
occurs in three different phases (chronic, accelerated, and blast phase), and is
usually diagnosed in the chronic phase. 8 Untreated chronic phase CML will
eventually progress to advanced phase in 3 to 5 years. 9 Imatinib, dasatinib, and
nilotinib are recommended as first-line TKI therapy for newly diagnosed patients with
chronic phase CML, followed by bosutinib and ponatinib as second line options.
8,10,11

Imatinib [Gleevec, Novartis], was the first TKI approved by the US Food and
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Drug Administration (FDA) for CML treatment in 2001, followed by dasatinib
[Sprycel, Bristol-Myers Squibb] in 2006, nilotinib [Tasigna, Novartis] in 2007, and
bosutinib [Bosulif, Pfizer] and ponatinib [Iclusig, Ariad Pharmaceuticals] in 2012. 12
TKIs play a large part in more than doubling the 5-year survival rate for CML
over the past two decades, from 31% for patients diagnosed in the early 1990’s to
66% for those diagnosed from 2006 to 2012. 2 The median survival used to be 4 to 6
years, but most CML patients treated with TKIs experience near normal life
expectancy, particularly those diagnosed before age 65 years. 13,14 Treating CML
with TKIs has differentiated the condition from solid cancers, turning it into a chronic,
manageable disease similar to diabetes, hypertension, and cardiovascular disorders.
7,10

Patients are required to continuously take their oral TKIs daily to produce the

anticipated benefit of long-term survival. 10,11 In addition, adherence to TKI therapy is
crucial in achieving optimal response and remaining free of disease progression. 15-17
Several studies have demonstrated that treatment interruptions and non-adherence
contribute to failure to achieve complete cytogenetic response (CCyR) 15-17, major
molecular response (MMR) 16, and complete molecular response (CMR) 15,16.
Much attention has been focused on the high cost of TKIs and whether these
costs inhibit patient use. 7 In the United States, patients may pay an average of 20%
of drug prices out-of-pocket [$20,000 - $30,000 per year, a quarter to a third of an
average household budget]. 7 Previous studies have shown that increased cost
sharing reduces the use of and adherence to prescription drugs. 18,19 One study that
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examined patient out-of-pocket expenditures in CML patients using imatinib found
that patients with higher spending were 42% more likely to be non-adherent and
70% more likely to discontinue their TKI therapy. 20
In this study, we examined the association between patient cost sharing with
TKI adherence, and also the impact of TKI adherence on subsequent healthcare
utilization and costs in commercially insured patients with newly diagnosed CML. We
are comprehensively studying the relationships among out-of-pocket costs,
adherence, and healthcare utilization or costs for new TKI users in a single study.
This study documents how non-adherence in treatment impacts healthcare
utilization and overall healthcare costs. Our study measured actual healthcare
utilization and costs to determine the effects on utilization patterns and direct
healthcare costs.
Methods
Data Source
We used the IBM® MarketScan® Commercial Database from January 1,
2011 to December 31, 2015. The MarketScan database provides inpatient,
outpatient, and pharmacy claims data from employer-based, commercially insured
group health plans in the United States, covering subscribers and dependents up to
age 65. All data were de-identified in accordance with the Health Insurance
Portability and Accountability Act (HIPAA) requirements.
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Sample Selection
We identified newly diagnosed CML patients with at least one prescription
claim for any of the five TKIs (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib)
between April 1, 2011, and December 31, 2014 (Figure 3). All these TKIs were
approved by the FDA for the treatment of CML and were available during the study
period. The first observed TKI dispensing date was considered the index claim. New
users of TKIs were defined as having no TKI prescription claims for at least 3
months before the index claim.
Patients were included if they were diagnosed with CML within twelve months
prior to the index claim. CML diagnosis is defined using International Classification
of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code for chronic
myeloid leukemia (205.1X) or International Classification of Diseases, Tenth
Revision, Clinical Modification [ICD-10-CM] code for chronic myeloid leukemia
(C92.1X).
Patients were excluded if they were a) younger than age 18 years at index
claim date, or turned 65 during the study period, and had b) no continuous
enrollment in the health plan and drug benefit in the 3 months before and 12 months
after the index claim (pre-index period and post-index period, respectively).
Study Variables
Measure for TKI out-of-pocket costs. We calculated the mean out-of-pocket costs
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for a 30-day supply of TKI medication. Out-of-pocket costs were defined as the sum
of the copayments, coinsurance, and deductibles paid by the patient at the time that
the TKI prescription was filled over the 12-month post-index period. We adjusted
out-of-pocket cost amounts for 60- or 90-day prescriptions to 30-day amounts. We
used the mean out-of-pocket costs per patient across repeated TKI prescriptions
dispensed in the 12-month post-index period and other patient characteristics to
predict TKI adherence.
Measure for TKI adherence. We estimated patient’s adherence to TKI using the
proportion of days covered (PDC). 21 The PDC calculation is based on the fill dates
and number of days supply for each fill of a prescription. The numerator is the total
number of days covered by the prescription fill during the 12-month post-index
period.
The sample was selected on the basis of imatinib, dasatinib, nilotinib,
bosutinib, or ponatinib initiation for CML treatment, but the adherence measure
included adherence to any TKI used during the study period since patients may have
been switched to another TKI (dasatinib, nilotinib, bosutinib, or ponatinib) because of
intolerance or failure to respond to the first TKI used. Patients were counted as using
a TKI for any day during which they had TKIs available during the post-index period.
If a person had overlapping supply of more than one TKI (e.g., he or she filled a
prescription for nilotinib before exhausting their supply of imatinib), then use of the
second medication was assumed to start the day after the end of the prior fill.
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The denominator is 365, the number of days between the index claim and the
end of the 12-month post-index period. The ratio was multiplied by 100 to obtain the
percentage of the proportion of days covered. Patients were classified as adherent
to TKIs if the PDC is greater than or equal to 80%. Clinical benefits are most likely to
occur when this threshold is exceeded. 15-17
Outcomes
Annual healthcare utilization. We assessed healthcare utilization during the 12month post-index period, using five distinct utilization measures: (1) number of
outpatient physician visits; (2) number of emergency room [ER] visits; (3) number of
all-cause hospitalizations; (4) number of CML-specific hospitalizations (identified as
any inpatient admission with an ICD-9-CM or ICD-10-CM code for CML as the
primary or secondary diagnosis); and (5) number of prescriptions.
Annual healthcare costs. We examined total direct healthcare costs during the 12month post-index period. We used the allowed amount to reflect direct costs, which
is the sum of plan paid, Coordination of Benefits and Other Savings (COB), and
patient out-of-pocket costs, including copayments, coinsurance, and deductibles. We
reported four distinct cost variables: (1) medical costs; (2) TKI pharmacy costs; (3)
non-TKI pharmacy costs; and (4) total all-cause healthcare costs.
Medical costs included costs associated with any inpatient or outpatient
encounter during the 12-month post-index period regardless of whether visits were
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related to CML or TKI-related toxicities. TKI pharmacy costs included costs
associated with pharmacy claims for imatinib, dasatinib, nilotinib, bosutinib, and
ponatinib during the 12-month post-index period. Non-TKI pharmacy costs
incorporated costs associated with any other pharmacy claims not included in the
TKI pharmacy related cost calculation. We converted costs ($US) to 2015 values
using the medical component of the Consumer Price Index.
Covariates
We reported patient demographic characteristics as of the index claim date,
such as patient age, sex, year of the index claim, region of residence (Northeast,
North Central, South, West), and the patient’s relationship to subscriber (subscriber
versus spouse or dependent). To account for possible changes in the patient’s
health plan type (comprehensive, preferred provider organization [PPO], point-ofservice [POS], consumer-driven health plan/high deductible health plan
[CDHP/HDHP], exclusive provider organization [EPO], health maintenance
organization [HMO]) during the 12-month post-index period, the plan type that the
patient had for most part of the year was determined to be the plan type under which
the patient was categorized.
We identified clinical characteristics using all available medical and pharmacy
claims for study patients in the 3-month pre-index period. These included DeyoCharlson comorbidity index as a measure of comorbidity burden, 22 the number of
unique drug classes filled as a measure of pill burden, and Darkow CML Complexity
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Index score (categorized as usual, moderate, or high, using reported diagnoses of
associated complications, comorbidities, or adverse events) as a measure of the
difficulty of managing patient’s disease 23. We used the starting dose of the index TKI
medication as a proxy for the phase of CML disease. 23,24 We calculated this dose as
the strength of TKI dispensed multiplied by the quantity filled, divided by the days’
supply on the pharmacy claim. For imatinib, the starting dose was categorized as
≤400mg [i.e., the typical starting dose for chronic phase CML] or ≥600mg [i.e., the
typical starting dose for accelerated phase or blast crisis]. 25 For dasatinib, the
starting dose was categorized as ≤100mg [i.e., the typical starting dose for chronic
phase CML] or ≥140mg [i.e., the typical starting dose for advanced phase].

26

For

nilotinib, the starting dose was categorized as ≤600mg [i.e., the typical starting dose
for chronic phase CML] or ≥800mg [i.e., the typical starting dose for accelerated
phase]. 27 For bosutinib, the starting dose was categorized as ≤500mg [i.e., the
typical starting dose for chronic, accelerated, or blast phase CML in patients
resistant to or intolerant to other therapies, including imatinib]. 28 For ponatinib, the
starting dose was categorized as ≤45mg [i.e., the typical starting dose for chronic,
accelerated, or blast phase CML in patients for whom no other TKI therapy is
indicated]. 29
An indicator variable for whether the patient had any TKI dose decrease was
used as a proxy for TKI adverse events during the 12-month post-index period
because TKI toxicities are managed by decreasing the initial dose prescribed. 8 The
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other control variable included was mean other out-of-pocket costs paid by the
patient for inpatient and outpatient services, and pharmacy medications (excluding
TKI medication) for the entire 12-month post-index period.
Statistical Analyses
Statistical comparisons between the characteristics of patients who were
adherent to TKI therapy (PDC≥80%) and patients who were non-adherent to TKI
therapy (PDC<80%) were conducted using the Wilcoxon-Mann-Whitney test for
continuous variables, and Pearson’s chi-squared test or the Fisher’s exact test (if
one or more cells have an expected frequency of five or less) for categorical
variables.
Adherence. The odds of being adherent to TKI versus being non-adherent in a 12month period was determined using a multivariate logistic regression model with
robust standard error estimates, controlling for potential confounding factors. The
adjusted risk ratio (ARR) and adjusted risk difference (ARD) were computed instead
of odds ratio since adherence was not considered to be a rare event. 30 The ARR is
the ratio of the mean predicted probabilities, 31 and denotes the probability of
adherence for each category of TKI out-of-pocket costs after controlling for potential
confounding factors. The ARD is the difference of the mean predicted probabilities, 31
and indicates differences in the absolute risk of adherence.
Healthcare utilization and costs. We compared healthcare utilization between the
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adherent and non-adherent patient cohorts using unadjusted and adjusted incidence
rate ratios (IRRs). Adjusted IRRs controlled for potential confounding factors and
were estimated using multivariate negative binomial regression models 32. We did
not require the inclusion of any offset variable because we observed all outcome
variables for one full year. We estimated unadjusted and adjusted cost differences
between the adherent and non-adherent patient cohorts using multivariate
generalized linear models with a gamma distribution and a log link, 23 controlling for
potential confounding factors.
All statistical analyses were performed using STATA version 15 (StataCorp
LP, College Station, Texas). Statistical significance was assumed at p-values less
than 0.05. The study protocol was considered exempt by The University of Texas
Health Science Center at Houston Institutional Review Board.
Results
Patient characteristics
867 patients were identified in the MarketScan database who were aged 1864 years and initiated TKI therapy following a new diagnosis of CML between April
1, 2011 and December 31, 2014. 45.9% of patients were on imatinib, 31.9% on
dasatinib, 21.8% on nilotinib, 0.2% on bosutinib, and 0.2% on ponatinib (Table 5).
Among this cohort, 58.8% of patients were non-adherent because they had fewer
than 80% of TKI medication days covered (PDC<80%) during the first year of
therapy.
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The mean ages of adherent and non-adherent patients were 51 years and 47
years, respectively. Most of the non-adherent patients were in the 18-39 (72.2%),
40-49 (64.7%), and 50-59 (51.7%) age groups, whereas the 60-64 age group had
more adherent patients (52.2%). 57.4% of adherent and 51.4% of non-adherent
patients were male, but the difference was not statistically significant (p=0.08). The
majority were enrolled in group health plans with richer benefits, which include
comprehensive, PPO, POS, and EPO, as shown by 75.6% of adherent and 73.9% of
non-adherent patients. Most patients also lived in the south; 37.0% of adherent
patients and 46.7% of non-adherent patients, and this is an inherent characteristic of
patients in the MarketScan data set.
Adherent patients initiated TKI therapy relatively quicker compared to nonadherent patients (37 days versus 67 days). More than 70% of patients who initiated
TKI after 3 months of CML diagnosis were non-adherent. Most patients were in the
chronic phase of CML; 94.4% of adherent patients and 86.9% of non-adherent
patients, respectively. 89.6% of adherent patients and 84.7% of non-adherent
patients did not switch TKI, whereas 87.4% of adherent patients and 82.3% of nonadherent patients did not have any TKI dose decrease during the 12-month postindex period. 52.7% of adherent patients reported having usual Darkow CML
Complexity Index scores compared to 64.1% of non-adherent patients. The 10 most
prevalent comorbidities found in the study cohorts are reported in Table 5.
The mean out-of-pocket costs for a 30-day supply of TKI medication were
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$126.77 (SD=234.29) for adherent patients and $188.48 (SD=639.07) for nonadherent patients, but the difference was not statistically significant (p=0.08). The
mean annual total of other out-of-pocket costs were $1,730.62 (SD=1,541.22) and
$1,848.22 (SD=1,892.38) for adherent and non-adherent patients, respectively, but
the difference was also not statistically significant (p=0.98).
In the unadjusted analysis, adherence to TKI was associated with out-ofpocket costs for TKI therapy, patient age, region of residence, index year of TKI
initiation, time to TKI drug index date from CML diagnosis date, index treatment, the
phase of CML disease, any TKI dose decrease, the Darkow CML Complexity Index
score, and concomitant medications.
Factors associated with TKI adherence
Out-of-pocket costs for TKI medication. We found that 30-day out-of-pocket costs
for TKI medication were significantly associated with the adjusted risk of adherence
(p<0.01). On average, copayments accounted for approximately 78.9% of the total
out-of-pocket costs for a 30-day supply of TKI medication, while coinsurance and
deductibles accounted for 11.8% and 9.3%, respectively.
Most patients (64.7%) have mean monthly out-of-pocket costs for TKI
medication above $0 and below $100. There is a positive association for each
increased category of out-of-pocket costs for TKI medication, controlling for potential
confounding factors until the highest category of out-of-pocket costs was reached
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(Table 6). On average, patients with a mean monthly out-of-pocket cost for TKI
medication above $400 were 1% less likely to be adherent to TKI compared to
patients with no out-of-pocket costs, after controlling for potential confounding
factors (95% CI, 0.66 to 1.47). In general, patients with higher TKI out-of-pocket
costs (≥75th percentile in the distribution of costs) that amounted to $100 or more for
a 30-day supply have lower predicted PDC by 2.4% (p<0.001).
Other patient characteristics. Older patients were more likely to be adherent to
TKI compared to younger patients as shown by each increased category of patient
age (60-64 versus 18-39: ARR, 1.60; 95% CI, 1.32-1.94; 50-59 versus 18-39: ARR,
1.61; 95% CI, 1.33-1.96). Patients in the geographical North Central and West
regions of the United States were significantly more likely to be adherent to TKI
compared to patients in the South (North Central: ARR, 1.25; 95% CI, 1.04 to 1.50;
West: ARR, 1.33; 95% CI, 1.10 to 1.61).
Patients with more time between CML diagnosis date and TKI drug index
claim date were less likely to be adherent to TKI (10-12 months versus 0-3 months:
ARR, 0.48; 95% CI, 0.25 to 0.94; 7-9 months versus 0-3 months: ARR, 0.47; 95%
CI, 0.22 to 1.04; 4-6 months versus 0-3 months: ARR, 0.61; 95% CI, 0.45 to 0.83).
Patients who were taking dasatinib and nilotinib were significantly more likely to be
adherent than patients taking imatinib (dasatinib: ARR, 1.25; 95% CI, 1.06 to 1.48;
nilotinib: ARR, 1.20; 95% CI, 1.00 to 1.45). Patients who had chronic phase CML
were also significantly more likely to be adherent compared to patients who were in
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the advanced phase (ARR, 1.49; 95% CI, 1.04 to 2.13). Patients who had their TKI
doses decreased (as a proxy for TKI adverse events) were significantly less likely to
be adherent to TKI (ARR, 0.75; 95% CI, 0.59 to 0.95). Patients who had high
Darkow CML Complexity Index were significantly more likely to be adherent
compared to patients who had the usual complexity (ARR, 1.22; 95% CI, 1.00 to
1.48). Patients were less likely to be adherent to TKI for every increase in preexisting condition that they had (ARR, 0.93; 95% CI, 0.89 to 0.99).
Copayments, coinsurance, and deductibles accounted for 44.2%, 29.0%, and
26.8% of total annual out-of-pocket costs for other prescription medication, and
inpatient and outpatient services. These other out-of-pocket costs were not
associated with adherence to TKI medication (p>0.05).
Healthcare utilization and costs
Non-adherent patients were observed to have greater healthcare utilization
compared to adherent patients, particularly utilization related to emergency room
visits and hospitalizations (Table 7). On an unadjusted basis, adherent patients were
estimated to be less likely to have all-cause hospitalizations (IRR=0.25, p<0.001), or
CML-specific hospitalizations (IRR=0.20, p<0.001). Adherent patients, however,
were estimated to be more likely to have a higher number of prescriptions
(IRR=1.31, p<0.001). This was observed in the higher average number of TKI
prescriptions (12.6 versus 6.8, p<0.001), and higher average number of non-TKI
prescriptions (25.8 versus 22.5, p=0.01) for adherent patients compared to non73

adherent patients. Adherent patients also had slightly more outpatient physician
visits (16.1 versus 15.3, p<0.001). After adjusting for potential confounding factors,
adherent patients were estimated to be less likely to have all-cause hospitalizations
(IRR=0.32; p<0.001), or CML-specific hospitalizations (IRR=0.30; p<0.01).
Among the components of unadjusted total annual all-cause healthcare costs
(adherent patients=$123,033; non-adherent patients=$103,887, p<0.001), TKI
pharmacy costs (adherent patients=$108,068; non-adherent patients=$74,045;
p<0.001) accounted for 87.8% and 71.3% of these costs, respectively (Table 8).
After adjusting for potential confounding factors, adherent patients incurred $19,222
more in total annual healthcare costs (p<0.001). Cost differences were mainly driven
by a TKI pharmacy cost difference of $29,061 (p<0.001) that was not offset by the
higher medical costs ($10,985, p<0.001) and higher non-TKI pharmacy costs
($1,642, p<0.01) incurred by non-adherent patients.
Discussion
In our study, the average adherence is 69.5% (median=76.4%), which is well
within the 69-79% range for proportion of days covered (PDC) reported in studies
based on claims data 33. For our study, we classified patients as adherent to TKIs if
they have PDC greater than or equal to 80% because literature shows that clinical
benefits are most likely to occur when this threshold is exceeded. 15-17 In our study
cohort with 867 patients, 41.2% were found to be adherent in their first year of
therapy after being newly diagnosed with CML. This is consistent with studies
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showing that 44-97% of CML patients were classified as being adherent to TKIs. 33
These studies reported a wide range of percentages that resulted from using
different methods to measure adherence, and the varying cut off (usually in the
range of 80-90%) to group adherent and non-adherent patients. 33
Out-of-pocket costs for the monthly supply of TKI medication averaged $164;
median out-of-pocket costs were $50 (range, $0-$9,079). Costs varied substantially
among individuals in our sample, with 7.2% having zero out-of-pocket costs, and
10.5% paying more than $300, which is double the estimated average monthly cost.
Most patients (64.7%) incurred out-of-pocket costs above $0 and less than $100. In
general, we observed that patients with TKI out-of-pocket costs of $100 or more
(≥75th percentile in the distribution of costs) for their monthly supply have lower
predicted PDC by 2.4% (p<0.001). This translates to approximately a nine-day
difference in days covered. The clinical implications of this non-adherence can be
significant, with patients who missed 10% of their daily doses (i.e., 3 days per
month) less likely to achieve a major molecular response and more likely to lose
cytogenetic response. 16,17,34
However, when we broke down the TKI out-of-pocket costs for a 30-day
supply into proportionate categories, we found a positive association for each
increased category of out-of-pocket costs for TKI medication, controlling for potential
confounding factors, until the highest category of out-of-pocket costs was reached at
$400. Our analyses may be regarded as the best-case scenario when evaluating the
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association between patient cost sharing and adherence to TKI because our study
population comprised commercially insured patients with relatively generous
employer-sponsored insurance (median out-of-pocket costs, $50 per fill) who filled at
least one TKI prescription. This may result in our study not capturing patients with
very high cost sharing who did not fill the first prescription. In addition, patients in our
study cohort are eligible for patient assistance or prescription assistance programs
that can help finance their TKI medication costs, allowing them to get their drugs free
or at reduced costs. 35 For instance, Novartis Pharmaceuticals Corporation has the
universal co-pay card for Gleevec and Tasigna in which patients are responsible for
up to the first $25 and the program pays the remaining co-pay or coinsurance until
the yearly maximum of $15,000 is reached. 36 Takeda Oncology has the co-pay
assistance program for Iclusig that limits patient’s co-pay or coinsurance to $10 per
month. 36
Our findings suggest that once patients are initiated on TKI therapy, the
monthly out-of-pocket costs that they incurred for their TKI medications may not be a
significant predictor of their adherence. We found that factors such as the time to
TKI drug index date from CML diagnosis date, and incidence of any TKI dose
decrease were significant predictors of adherence. Patients who initiated TKI later
than three months after CML diagnosis were significantly associated with 39-53%
lower likelihood of adherence to TKI. This was consistent with how a long lag time
between CML diagnosis and therapy initiation was associated with higher non76

adherence. 15,37-40 In addition, patients who experienced any adverse effects from the
drug (based on observed TKI dose decreases) were significantly associated with
25% lower likelihood of adherence to TKI. This was consistent with other studies that
reported patients experiencing adverse effects from the medication were more likely
to be non-adherent. 16,33,37,38,41,42
The main finding is that non-adherent patients experienced higher levels of
healthcare utilization. They were more likely to have more frequent hospitalizations,
regardless of whether it is CML-specific or otherwise, compared to adherent patients
(both p<0.05). This is consistent with a previous study reporting that low adherence
was associated with more than 10 times higher frequency of inpatient visits
compared to patients with high adherence. 43 The more frequent hospitalizations,
however, did not convert into higher total all-cause healthcare costs (p<0.05) in spite
of non-adherent patients incurring higher medical costs and non-TKI pharmacy costs
(both p<0.05). These were more than offset by higher TKI medications costs
incurred by the adherent patients (p<0.05). These findings contrast with reports of
costly non-pharmacologic medical services due to treatment failures. 43-45
Our findings have important implications. To the best of our knowledge, this is
the first study to research the association between patient cost sharing, adherence
to TKI, and subsequent healthcare utilization and costs in a population of
commercially insured patients newly diagnosed with CML. Non-adherence to TKI
medication may put patients at increased risk of treatment failure due to resistant
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CML. 16,17 The success story of TKIs show how effective but expensive novel
anticancer drugs will continue improving patient outcomes and expanding treatment
options, but patients and insurers are left to bear the increasing financial burden. 46
Despite their high cost, optimal use of TKIs has generated substantial health
improvements for CML patients, and can reduce the economic burden of CML for
insurers through decreased healthcare utilization. 23,43,46,47 Future research should
focus on interventions to improve TKI adherence by exploring the role that
physicians and pharmacists can play to ensure that patients are initiated on TKI
immediately after a diagnosis of CML. A delay in TKI initiation could decrease
adherence that will affect treatment response, which can result in patients requiring
stem-cell transplantation, worse clinical outcomes, and potentially shorter life
expectancy. 48,49
The study is subject to some limitations. As with all observational studies,
there is the potential for unobserved confounding since our claims data lack certain
clinical or treatment history variables, and socioeconomic factors. We used
multivariate regressions with proxies found in the literature to control for these
unavailable sociodemographic and clinical characteristics to offset the limitations of
our observational design. Other limitations common to studies using administrative
claims data, such as claims coding errors and missing data, may apply in this study.
Nonetheless, claims data have the advantage of being a valid, large-sample source
of real-world practice data. 50
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The use of insurance claims data included information on filled prescriptions
only. Assessing adherence using prescription claims assumes that patients are
taking medications as consistently as they fill their prescriptions. These databases
also do not provide information on the reasons for patients to stop their medications
(e.g., doctor’s advice due to medication side effects or ineffectiveness). In some
cases, our results may be underestimating the true adverse impact of high cost
sharing if patients have supplemental cost-sharing help from patient assistance
programs. Despite these shortcomings, pharmacy and insurance records provide the
most accurate estimate of actual medication use in large populations over extended
periods of time. 51,52
We have unequal numbers of patients on the five different TKIs observed in
our 5-year study period due to the varying years of TKI approval by the FDA for CML
treatment. Imatinib, dasatinib, and nilotinib were the first three TKIs approved by the
FDA for CML treatment in 2001, 2006, and 2007, respectively. 12 Bosutinib and
ponatinib were relatively new drugs at the time of the study since the FDA approved
these two TKIs for CML treatment in 2012. 12 Future research should take into
consideration the rapidly evolving landscape of available TKIs and frontline therapy
recommendations for treating CML. 48
Conclusions
Our study suggests that CML patients with lower TKI out-of-pocket costs were
more adherent and experienced lower healthcare utilization, resulting in medical
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service cost savings. Patients with better adherence were at lower risk of adverse
events such as hospitalizations. These lower medical costs, however, were more
than offset by higher TKI medication costs observed during the first year of TKI
therapy. This research provides critical new evidence to physicians and pharmacists
in suggesting that high drug out-of-pocket costs may limit initial access to life-saving
oral anticancer medications that subsequently impact patient adherence.
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Table 5: Baseline Characteristics of Patients Newly Diagnosed With CML Receiving
TKI Therapy
Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

(n = 510)

(n = 357)

46.67±11.26 [49]

50.82±10.28 [53]

Percent
a
adherent

pb
value

Demographic
characteristics
Age at the index
date, years,
mean±SD [median]

48.38±11.05 [51]

<0.001
c

Age group, years, n

<0.001
c

18 – 39

187 (21.6%)

135 (26.5%)

72.2%

52 (14.6%)

27.8%

40 – 49

221 (25.5%)

143 (28.0%)

64.7%

78 (21.8%)

35.3%

50 – 59

323 (37.2%)

167 (32.7%)

51.7%

156 (43.7%)

48.3%

60 – 64

136 (15.7%)

65 (12.8%)

47.8%

71 (19.9%)

52.2%

467 (53.9%)

262 (51.4%)

56.1%

205 (57.4%)

43.9%

Male, n
Patient’s
relationship to
subscriber, n

0.46

Subscriber

568 (65.5%)

329 (64.5%)

57.9%

239 (66.9%)

42.1%

Spouse or
dependent

299 (34.5%)

181 (35.5%)

60.5%

118 (33.1%)

39.5%

Health plan type,
n
Group:
Comprehensive
/ Preferred
provider
organization /
Point-of-service
/ Exclusive
provider

0.08

0.12
647 (74.6%)

377 (73.9%)

92

58.3%

270 (75.6%)

41.7%

Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

(n = 510)

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

Percent
a
adherent

pb
value

(n = 357)

organization
Consumerdriven health
plan / high
deductible
health plan

85 (9.8%)

47 (9.2%)

55.3%

38 (10.6%)

44.7%

Health
maintenance
organization

96 (11.1%)

56 (11.0%)

58.3%

40 (11.2%)

41.7%

Missing /
Unknown

39 (4.5%)

30 (5.9%)

76.9%

9 (2.5%)

23.1%

Region of
residence, n

0.03

Northeast

165 (19.0%)

96 (18.8%)

58.2%

69 (19.3%)

41.8%

North Central

177 (20.4%)

94 (18.4%)

53.1%

83 (23.3%)

46.9%

South

370 (42.7%)

238 (46.7%)

64.3%

132 (37.0%)

35.7%

West

139 (16.0%)

71 (13.9%)

51.1%

68 (19.0%)

48.9%

16 (1.8%)

11 (2.2%)

68.8%

5 (1.4%)

31.3%

Unknown
Index year, n

0.04

2011

298 (34.4%)

192 (37.6%)

64.4%

106 (29.7%)

35.6%

2012

200 (23.1%)

121 (23.7%)

60.5%

79 (22.1%)

39.5%

2013

204 (23.5%)

108 (21.2%)

52.9%

96 (26.9%)

47.1%

2014

165 (19.0%)

89 (17.5%)

53.9%

76 (21.3%)

46.1%

54.31±73.30
[21]

66.99±81.46
[27.5]

Time to drug
index date from
diagnosis date,
days, mean±SD

93

36.18±54.99
[15]

c

c

<0.001
c

Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

(n = 510)

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

Percent
a
adherent

pb
value

(n = 357)

[median]
Time group,
months, n

<0.001
c

0–3

689 (79.5%)

373 (73.1%)

54.1%

316 (88.5%)

45.9%

4–6

115 (13.3%)

85 (16.7%)

73.9%

30 (8.4%)

26.1%

7–9

30 (3.5%)

25 (4.9%)

83.3%

5 (1.4%)

16.7%

10 – 12

33 (3.8%)

27 (5.3%)

81.8%

6 (1.7%)

18.2%

Index treatment, n

<0.001
c

Imatinib
Started on ≤400
mg/day

360 (41.5%)

227 (44.5%)

63.1%

133 (37.2%)

36.9%

Started on ≥600
mg/day

38 (4.4%)

31 (6.1%)

81.6%

7 (2.0%)

18.4%

Started on ≤100
mg/day

265 (30.6%)

133 (26.1%)

50.2%

132 (37.0%)

49.8%

Started on ≥140
mg/day

11 (1.3%)

9 (1.8%)

81.8%

2 (0.6%)

18.2%

Started on ≤600
mg/day

155 (17.9%)

83 (16.3%)

53.5%

72 (20.2%)

46.5%

Started on ≥800
mg/day

34 (3.9%)

25 (4.9%)

73.5%

9 (2.5%)

26.5%

Dasatinib

Nilotinib
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Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

(n = 510)

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

Percent
a
adherent

pb
value

(n = 357)

Bosutinib
Started on
≤500mg/day

2 (0.2%)

1 (0.2%)

50.0%

1 (0.3%)

50.0%

2 (0.2%)

1 (0.2%)

50.0%

1 (0.3%)

50.0%

780 (90.0%)

443 (86.9%)

56.8%

337 (94.4%)

43.2%

Ponatinib
Started on
≤45mg/day
CML chronic
phase, n
Any switching of
TKI, n
Yes

115 (13.3%)

78 (15.3%)

67.8%

37 (10.4%)

32.2%

No

752 (86.7%)

432 (84.7%)

57.4%

320 (89.6%)

42.6%

Any TKI dose
decrease, n
Yes

135 (15.6%)

90 (17.7%)

66.7%

45 (12.6%)

33.3%

No

732 (84.4%)

420 (82.3%)

57.4%

312 (87.4%)

42.6%

Darkow CML
Complexity Index,
n

c

0.04

c

0.04

c

<0.01

Usual

515 (59.4%)

327 (64.1%)

63.5%

188 (52.7%)

36.5%

Moderate

208 (24.0%)

112 (22.0%)

53.8%

96 (26.9%)

46.2%

High

144 (16.6%)

71 (13.9%)

49.3%

73 (20.4%)

50.7%

2.39±1.14 [2]

2.39±1.25 [2]

Deyo-Charlson
comorbidity
index, mean±SD
[median]

<0.001

95

2.38±0.96 [2]

0.33

c

Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

(n = 510)

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

Percent
a
adherent

pb
value

(n = 357)

10 most prevalent
d
comorbidities, n

-

d

Diabetes

93 (10.7%)

57 (11.2%)

61.3%

36 (10.1%)

38.7%

Chronic
obstructive
pulmonary

55 (6.3%)

30 (5.9%)

54.5%

25 (7.0%)

45.5%

Acute
myocardial

17 (2.0%)

13 (2.6%)

76.5%

4 (1.1%)

23.5%

Renal

16 (1.8%)

9 (1.8%)

56.3%

7 (2.0%)

43.8%

Cerebrovascular

15 (1.7%)

5 (1.0%)

33.3%

10 (2.8%)

66.7%

Metastatic
cancer

15 (1.7%)

12 (2.4%)

80.0%

3 (0.8%)

20.0%

Congestive
heart

13 (1.5%)

8 (1.6%)

61.5%

5 (1.4%)

38.5%

Rheumatoid
disease

11 (1.3%)

7 (1.4%)

63.6%

4 (1.1%)

36.4%

Diabetes with
complications

11 (1.3%)

4 (0.8%)

36.4%

7 (2.0%)

63.6%

Peripheral
vascular

7 (0.8%)

4 (0.8%)

57.1%

3 (0.8%)

42.9%

Concomitant
medications /
Number of unique
drug classes,
mean±SD
[median]

4.80±3.36 [4]

4.50±3.28 [4]

5.23±3.42 [5]

<0.001

Out-of-pocket
costs for a 30-day
supply of TKI
medication,
mean±SD

163.07±513.35
[49.39]

188.48±639.07
[45.07]

126.77±234.29
[55.81]

0.08

96

c

Total number of
patients
(n = 867)

Patient who are
non-adherent to
TKI therapy (PDC
< 80%)

Percent
nona
adherent

(n = 510)

Patient who are
adherent to TKI
therapy (PDC ≥
80%)

Percent
a
adherent

pb
value

(n = 357)

[median]
Out-of-pocket
costs group, n
$0

<0.05
62 (7.2%)

36 (7.1%)

58.1%

26 (7.3%)

41.9%

>$0 – $100

561 (64.7%)

342 (67.1%)

61.0%

219 (61.3%)

39.0%

>$100 – $200

110 (12.7%)

55 (10.8%)

50.0%

55 (15.4%)

50.0%

>$200 – $300

43 (5.0%)

22 (4.3%)

51.2%

21 (5.9%)

48.8%

>$300 – $400

17 (2.0%)

6 (1.2%)

35.3%

11 (3.1%)

64.7%

>$400

74 (8.5%)

49 (9.6%)

66.2%

25 (7.0%)

33.8%

1,799.80±
1,756.32
[1,255.29]

1,848.22±
1,892.38
[1,240.04]

Other out-ofpocket costs,
annual total,
mean±SD
e
[median]

1,730.62±
1,541.22
[1,338.48]

0.98

Other out-ofpocket costs
group, n

0.56

$0–$1,000

353 (40.7%)

213 (41.8%)

60.3%

140 (39.2%)

39.7%

>$1,000–$2,000

227 (26.2%)

128 (25.1%)

56.4%

99 (27.7%)

43.6%

>$2,000–$3,000

135 (15.6%)

75 (14.7%)

55.6%

60 (16.8%)

44.4%

>$3,000

152 (17.5%)

94 (18.4%)

61.8%

58 (16.3%)

38.2%

a

Percentages for non-adherent and adherent patients were calculated using the total number of
patients in each corresponding line item (for categorical variables) instead of n=867 as the
denominator.
b
Comparing the differences between non-adherent and adherent TKI patients. Continuous variables
were compared using the Wilcoxon-Mann-Whitney test. Categorical variables were compared using
Pearson’s chi-squared test or the Fisher’s exact test if one or more cells have an expected frequency
of five or less.
c
Significant at the 5% level.
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c

d

Comorbidities presented were the 10 most prevalent of the 17 Deyo-Charlson conditions among
patients in the study cohort excluding cancer. P-values not presented because data is too sparse.
e
Other out-of-pocket costs include services for outpatient, inpatient, and medications (non-TKI)
during the post-index period for which patients had TKI therapy.
CML indicates chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.
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Table 6: Adjusted Risk Ratio (ARR) and Adjusted Risk Difference (ARD) of
Adherence to TKI Medication Among Patients Newly Diagnosed With CML (n=867)
Characteristics

ARR

a

95% CI

ARD

a

95% CI

Mean out-of-pocket costs
for a 30-day supply of TKI
b
medication
$0

Reference

>$0 – $100
>$100 – $200

b

>$200 – $300
>$300 – $400

b

>$400
Age at the index date, years

Reference

1.05

0.79 to 1.40

0.02

-0.10 to 0.14

1.46

1.12 to 1.90

0.18

0.04 to 0.32

1.33

0.93 to 1.89

0.13

-0.06 to 0.32

1.62

1.11 to 2.36

0.25

0.01 to 0.50

0.99

0.66 to 1.47

-0.01

-0.17 to 0.16

b

18 – 39

Reference

Reference

40 – 49

1.21

0.99 to 1.49

0.08

-0.01 to 0.18

50 – 59

b

1.61

1.33 to 1.96

0.21

0.12 to 0.29

60 – 64

b

1.60

1.32 to 1.94

0.23

0.12 to 0.33

Male versus female

1.12

0.96 to 1.31

0.05

-0.02 to 0.11

Subscriber (yes versus no)

1.12

0.95 to 1.32

0.05

-0.02 to 0.11

Health plan type
Group: Comprehensive /
Preferred provider
organization / Point-ofservice / Exclusive provider
organization

Reference

Reference

Consumer-driven health
plan / high deductible
health plan

1.01

0.77 to 1.34

0.01

-0.11 to 0.12

Health maintenance
organization

0.90

0.70 to 1.16

-0.04

-0.14 to 0.06
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Characteristics

ARR

Missing / Unknown
Region of residence

0.73

ARD

0.44 to 1.23

-0.11

Reference

Northeast
North Central

a

95% CI

95% CI
-0.27 to 0.05

b

South

West

a

b

b

Unknown

Reference

1.18

0.97 to 1.43

0.07

-0.02 to 0.16

1.25

1.04 to 1.50

0.10

0.01 to 0.18

1.33

1.10 to 1.61

0.13

0.04 to 0.22

0.81

0.41 to 1.58

-0.08

-0.30 to 0.14

Index year
2011

Reference

Reference

2012

0.97

0.78 to 1.19

-0.01

-0.10 to 0.07

2013

1.14

0.94 to 1.38

0.06

-0.03 to 0.14

2014

1.11

0.90 to 1.37

0.04

-0.05 to 0.14

Time to drug index date
from diagnosis date,
b
months
0–3

Reference

Reference

4–6

b

0.61

0.45 to 0.83

-0.17

-0.26 to -0.08

7–9

b

0.47

0.22 to 1.04

-0.22

-0.38 to -0.06

0.48

0.25 to 0.94

-0.22

-0.35 to -0.08

10 – 12

b

Index treatment
Imatinib

Reference

Dasatinib

b

Reference

1.25

1.06 to 1.48

0.10

0.02 to 0.17

b

1.20

1.00 to 1.45

0.08

-0.00 to 0.16

Bosutinib

1.55

0.68 to 3.53

0.23

-0.30 to 0.75

Ponatinib

1.61

0.44 to 5.86

0.25

-0.60 to 1.11

Nilotinib
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Characteristics

ARR

Chronic phase CML (yes
b
versus no)
Any TKI dose decrease (yes
b
versus no)

a

a

95% CI

ARD

95% CI

1.49

1.04 to 2.13

0.14

0.03 to 0.24

0.75

0.59 to 0.95

-0.11

-0.19 to -0.03

Darkow CML Complexity
Index
Usual

Reference

Reference

Moderate

1.13

0.95 to 1.35

0.05

-0.02 to 0.13

b

1.22

1.00 to 1.48

0.09

-0.00 to 0.18

Deyo-Charlson comorbidity
b,c
index

0.93

0.89 to 0.99

-0.03

-0.06 -to 0.00

Concomitant medications /
Number of unique drug
c
classes

1.02

1.00 to 1.05

0.01

-0.00 to 0.02

High

Mean other out-of-pocket
d
costs, annual total
$0 – $1,000

Reference

Reference

>$1,000 – $2,000

0.98

0.80 to 1.19

-0.01

-0.09 to 0.07

>$2,000 – $3,000

0.94

0.74 to 1.20

-0.02

-0.12 to 0.07

>$3,000

0.80

0.62 to 1.03

-0.08

-0.18 to 0.01

a

ARR and ARD were determined using a multivariate logistic regression model with robust standard
error estimates.
b
Significant at the 5% level.
c
Treated as continuous.
d
Other out-of-pocket costs include services for outpatient, inpatient, and medications (non-TKI)
during the post-index period for which patients had TKI therapy.
ARD indicates adjusted risk difference; ARR, adjusted risk ratio; CI, confidence interval; CML, chronic
myeloid leukemia; TKI, tyrosine kinase inhibitor.
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Table 7: Comparison of Healthcare Utilization Between Adherent and Non-Adherent
TKI Patients
Average Annual Utilization
(mean±SD)
Adherent
Patients

NonAdherent
Patients

Unadjusted
IRR

a

Adjusted

p-value

IRR

a

p-value

(n = 357)
(n = 510)
Outpatient
physician visits

16.04±9.00

15.25±12.26

1.05

0.27

0.99

0.89

Emergency
room (ER)
visits

0.52±1.59

0.63±1.79

0.82

0.34

0.85

0.37

All-cause
hospitalizations

0.06±0.29

0.25±0.95

0.25

<0.001

b

0.32

<0.001

CML-specific
hospitalizations

0.03±0.19

0.15±0.72

0.20

<0.001

b

0.30

<0.01

38.39±27.23

29.27±27.52

1.31

<0.001

b

1.27

<0.001

Number of
prescriptions
(all drugs)
a

b

b

b

An IRR<1 indicates that adherent patients had lower incidence of incurring medical services
compared to non-adherent patients. IRR were estimated using multivariate negative binomial
regressions.
b
Significant at the 5% level.
CML indicates chronic myeloid leukemia; IRR, incidence rate ratio; TKI, tyrosine kinase inhibitor.
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Table 8: Comparison of Healthcare Costs Between Adherent and Non-Adherent TKI
Patients
Average Annual Costs (mean±SD)

Unadjusted

Adherent Patients

Non-Adherent Patients

(n = 357) [A]

(n = 510) [B]

Cost
a
Difference

Adjusted

p-value

Cost
a
Difference
(beta
coefficient)

p-value

[A] – [B]
Medical
costs

13,015.20±21,034.70

26,966.60±80,379.80

-13,951.40

<0.001

b

-10,984.74
(-.42)

<0.001

b

TKI
pharmacy
costs

108,068.00±26,991.10

74,044.50±38,453.70

34,023.50

<0.001

b

29,060.22
(.32)

<0.001

b

Non-TKI
pharmacy
costs

1,950.16±3,541.10

2,875.54±7,269.88

-925.38

<0.01

-1,641.29
(-.36)

<0.01

Total allcause
healthcare
costs

123,033.00±35,576.90

103,887.00±89,574.10

19,146.00

<0.001

19,221.90
(.17)

<0.001

a

b

b

Cost differences <0 indicate that non-adherent patients incurred higher healthcare costs. Cost
differences were estimated using multivariate generalized linear models with a gamma distribution
and a log link.
b
Significant at the 5% level.
TKI indicates tyrosine kinase inhibitor.

103

b

b

Figure 3: Study Cohort Selection and Subject Exclusion

At least one claim for TKI (index claim)
between January 1, 2011, and
December 31, 2015
(n = 6,680)

Exclude patients without a CML diagnosis
(ICD-9-CM code 205.1X or ICD-10-CM code
C92.1X) within 12 months prior to index claim
(n = 3,446)

Exclude patients who did not have continuous
health plan enrollment from 3 months before
and 12 months after their index claim
(n = 2,329)

Exclude patients who did not have continuous
drug benefit from 3 months before and 12
months after their index claim
(n = 27)

Exclude patients younger than age 18 years
or who turned 65 during the study period
(n = 11)

Final cohort for analysis
(n = 867)
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CONCLUSION
Patients initiating anticancer drugs face high out-of-pocket costs because
prescription drug plans in the United States tend to have cost-sharing mechanisms
to control the high costs of these medications. Despite the high costs of TKIs, their
optimal use has generated substantial health improvements for CML patients that
can reduce the economic burden of CML for insurers through decreased healthcare
utilization. We used commercial insurance claims data to show that high costs of
TKIs in patients newly diagnosed with CML may be associated with non-adherence.
Patients with early initiation of TKI and better adherence had lower risk of adverse
events such as hospitalizations, resulting in potential medical service cost savings.
Our research studied the association among drug out-of-pocket costs, initiation or
adherence, and healthcare utilization or costs within a single study, which is a more
comprehensive approach than those found in literature. We measured actual
healthcare utilization and costs to determine the effects of initiation or adherence on
utilization patterns and direct healthcare costs. Our study documented how TKI
initiation delays or non-adherence in CML treatment impacts healthcare utilization
and overall healthcare costs. Limitations common to studies using administrative
claims data apply in our study, such as potential unobserved confounding, claims
coding errors, and missing data. Our use of insurance claims data included
information on filled prescriptions only. This prevents us from distinguishing between
patients who did not receive a prescription, and patients who received a prescription
105

but did not fill it. We also assume that patients are taking medications as consistently
as they fill their prescriptions. Claims data also do not provide information on the
reasons for patients to stop their medications, or any supplemental cost-sharing help
patient could have received from patient assistance programs. Future research
should focus on assessing barriers to timely access to healthcare for early diagnosis
of CML and optimal TKI adherence to advance the understanding of and eliminate
health disparities in cancer.
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